$TYME Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO

NEW YORK, Dec. 19, 2017 — Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that efficacy data from its lead therapy SM-88 in patients with advanced or metastatic pancreatic cancer will be presented in a poster session at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, to be held Jan. 18-20, 2018, at the Moscone West Building in San Francisco, Calif.

Details on the poster are as follows:

Title: SM-88 therapy in patients with advanced or metastatic pancreatic cancer
Abstract Number: 457
Poster Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Poster Board Number: M4
Date / Time: Friday, Jan. 19, 11:30 a.m. – 1 p.m., and 5:30 p.m. – 6:30 p.m. PST
Location: Moscone West Building, Level 1
Presenter: Giuseppe Del Priore, M.D., Chief Medical Officer, Tyme

Additional information on the meeting can be found on the ASCO Gastrointestinal Cancers Symposium website: https://gicasym.org/.

About SM-88

SM-88 is a potential first-in-class combination therapy that utilizes a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells, breaking down the cells’ key defenses and making them vulnerable to oxidative stress and death. SM-88 has demonstrated efficacy in the treatment of multiple oncology indications, including breast and prostate cancer, without report of significant toxicity or serious adverse events.

SM-88 is being evaluated in a Phase II clinical trial for prostate cancer (NCT02796898). A Phase II clinical trial in pancreatic cancer is planned for initiation in the first quarter of 2018.

About Tyme

Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Tyme’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer. The Company is preparing to initiate an additional Phase II clinical trial in pancreatic cancer in early 2018.

For more information, visit www.tymeinc.com.

Forward-Looking Statements/Disclosure Notice

In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88), their clinical potential and non-toxic safety profiles, our drug development plans and strategies, our completed studies, ongoing and planned clinical trials, preliminary data results and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such as “anticipates,” “believes,” “designed,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of Tyme’s control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, including the ability to achieve clinical study start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final Phase II data analysis, final results of additional clinical trials, or both, may be different from the preliminary data analysis and may not support further clinical development; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; competitive developments; and the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on June 12, 2017 and Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 3, 2017 (available at www.sec.gov). The data set forth in these updated analyses are not necessarily predictive of future patient or clinical data outcomes.

The information contained in this press release is as of release date and Tyme assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

Contacts

Tyme Inc.
Jonathan Eckard
Chief Scientific Affairs Officer
jon.eckard@tymeinc.com

ICR Healthcare
Investors
Stephanie Carrington
Stephanie.Carrington@icrinc.com
646-277-1282

6 Degrees
Media
Sarah Hall
shall@6degreespr.com
215-313-5638

$TMQ New Large Shareholder, CEO Significantly Increases his Share Position

VANCOUVER, Dec. 19, 2017 – Trilogy Metals Inc. (TSX/NYSE American: TMQ) (“Trilogy Metals” or “the Company”) announces that a wholly-owned subsidiary of South32 Limited (ASX/JSE/LSE: S32) (“South32“) has become a new significant shareholder of the Company owning approximately 6.5 million common shares of the Company or approximately 6% of the outstanding common shares.  Rick Van Nieuwenhuyse, the Company’s Chief Executive Officer has also increased his shareholdings of Trilogy Metals by approximately 1.7 million shares, owning approximately 2.8 million common shares of the Company or approximately 2.6%.  South32 and Mr. Van Nieuwenhuyse have purchased shares from a previous shareholder.

Concurrently, Trilogy Metals has given South32 participation rights in future financings to participate at a minimum of 20% to a maximum of 40% in future financings, private or public, to a maximum ownership of 19.9% in the Company.  This right expires if South32 does not participate for the lesser of 20%, or that number of shares that would not put them past a 19.9% ownership interest in the Company, in any particular financing.

“We are excited to have South32 as a significant shareholder and joining our other large shareholders: Electrum, Paulson and Baupost. Together with our strong supportive shareholders the Company expects to advance development of the Arctic and Bornite projects in the Ambler mining district.  It is an exciting time to be a Trilogy shareholder and I am pleased to personally be ALL-IN on Ambler!”, comments Rick Van Nieuwenhuyse, President and CEO of Trilogy Metals.

About Trilogy Metals

Trilogy Metals Inc. is a metals exploration company focused on exploring and developing the Ambler mining district located in northwestern Alaska. It is one of the richest and most-prospective known copper-dominant districts located in one of the safest geopolitical jurisdictions in the world. It hosts world-class polymetallic VMS deposits that contain copper, zinc, lead, gold and silver, and carbonate replacement deposits which have been found to host high grade copper mineralization. Exploration efforts have been focused on two deposits in the Ambler mining district – the Arctic VMS deposit and the Bornite carbonate replacement deposit. Both deposits are located within the Company’s land package that spans approximately 143,000 hectares. The Company has an agreement with NANA Regional Corporation, Inc., a Regional Alaska Native Corporation that provides a framework for the exploration and potential development of the Ambler mining district in cooperation with local communities. Our vision is to develop the Ambler mining district into a premier North American copper producer.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, including, without limitation, the development of the Arctic and Bornite projects in the Ambler mining district, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the uncertainties involving the need for additional financing to explore and develop properties and availability of financing in the debt and capital markets; uncertainties involved in the interpretation of drilling results and geological tests and the estimation of reserves and resources; the need for cooperation of government agencies and native groups in the development and operation of properties as well as the construction of the access road; the need to obtain permits and governmental approvals; risks of construction and mining projects such as accidents, equipment breakdowns, bad weather, non-compliance with environmental and permit requirements, unanticipated variation in geological structures, metal grades or recovery rates; unexpected cost increases, which could include significant increases in estimated capital and operating costs; fluctuations in metal prices and currency exchange rates; and other risks and uncertainties disclosed in the Company’s Annual Report on Form 10-K for the year ended November 30, 2016 filed with Canadian securities regulatory authorities and with the United States Securities and Exchange Commission and in other Company reports and documents filed with applicable securities regulatory authorities from time to time. The Company’s forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made. The Company assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change, except as required by law.

$KYI CyberCore Picks BIO-key Biometric Software for NIST-Compliant Multi-Factor Authentication

WALL, N.J., Dec. 19, 2017  — BIO-key International, Inc. (NASDAQ:BKYI), an innovative provider of biometric software and hardware systems and consumer products that offer strong, convenient security and user access, today reported that CyberCore Technologies has agreed to deploy BIO-key’s ID Director for Windows software authentication platform. ID Director integrates with Microsoft Active Directory to deliver complaint, multi-factor biometric authentication that meets the strict compliance demands set forth for government contractors gaining access to critical files and information.

With annual revenues of over $100 million, CyberCore is a leading provider of Value Added Services, Professional Services, and Managed Services for government and commercial customers. To participate in government projects, the company is required to meet the National Institute of Standards and Technologies (NIST) multi-factor authentication guidelines.

“Thanks to the excellent support from the BIO-key team, CyberCore has met the multi-factor authentication requirements of the NIST 800-171 standard, by utilizing its ID Director solution. CyberCore selected BIO-key for multi-factor authentication because of its proven security, quick implementation and seamless integration into our IT environment,” said Dr. William J. Von Hagel, Jr., Sales Operations Director at CyberCore Technologies.

“We are seeing solid demand for our flexible, multi-factor authentication solutions from customers working with government agencies,” stated Mike DePasquale, BIO-key CEO. “This customer needed an interoperable solution that was compatible with existing third-party hardware and integrated with Active Directory. ID Director met this requirement in a secure and cost effective manner while also providing ease of management and compliant access to secure files and applications.”

About CyberCore Technologies
CyberCore Technologies is the leading provider of Secure Supply Chain Management and Cyber Solutions focused on protecting our customer’s environment from external and internal threats. With 17 years of experience, ISO 28000:2007 certified risk management processes, and ISO 20243:2015 certified counterfeit mitigation procedures, CyberCore provides Value Added Services, Professional Services, and Managed Services for government and commercial customers. The company’s success is founded on strong relationships – both with customers and with teammates. CyberCore seeks to first understand, ensuring that solutions not only meet current challenges, but stand the test of time. For further information on CyberCore Technologies, visit http://www.cybercoretech.com.

About BIO-key International, Inc. (www.bio-key.com)
BIO-key is revolutionizing authentication with biometric solutions that enable convenient and secure access to devices, information, applications and high-value transactions. BIO-key’s software and hardware finger scanning solutions offer secure, user-friendly and attractively priced alternatives to passwords, PINs, tokens and security cards, enabling enterprises and consumers to secure their networks and devices as well as their information in the cloud.

Now BIO-key’s TouchLock line of fingerprint and Bluetooth-enabled padlocks brings the security and ease of use of biometric technology to your home, office, school, gym or pastimes. Available at a growing base of retail and e-tail outlets and via www.shopbio-key.com, these innovative padlocks provide even more ways to “BIO-key your world.”

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue, our ability to develop new products and evolve existing ones, market acceptance of biometric solutions generally and our specific offerings, our ability to expand into the Asian market, the impact on our business of the past financial crisis in the global capital markets, and our ability to attract and retain key personnel.  For a more complete description of these and other risk factors that may affect the future performance of BIO-key International, Inc., see “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made.

Facebook – Corporate:       BIO-key International
Twitter – Corporate:            @BIOkeyIntl
Twitter – Investors:             @BIO_keyIR
StockTwits:                          @BIO_keyIR

Investor & Media Contacts
William Jones, Tanya Kamatu
Catalyst Global
212-924-9800
bkyi@catalyst-ir.com

$PFNX $18.5 Million Worldwide License and Option Agreement with Jazz Pharmaceuticals

SAN DIEGO, Dec. 19, 2017 — Pfenex Inc. (NYSE AMERICAN: PFNX) today announced the amendment of the 2016 agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.

Under the amended agreement, Pfenex will be eligible to receive an additional $43.5 million in amendment fee and development milestone payments as compared to the 2016 agreement, increasing the total value of upfront, option and amendment fee payments and potential payments for the achievement of development, regulatory and sales-related milestones associated with the collaboration to an aggregate of $224.5 million.  Pfenex will also continue to be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration, at rates reduced from those under the 2016 agreement.

Additionally, Pfenex announced today that, pursuant to the amended agreement, in the fourth quarter it earned $18.5 million in connection with the collaboration by achieving a $13.5 million development milestone and receiving a $5 million payment following signing of the amended agreement. The remaining development, regulatory and sales-related milestones that could potentially be earned total $189.25 million.

“Our collaboration with Jazz Pharmaceuticals is mutually beneficial and the updated agreement is another solid example of the strong collaboration.  We look forward to continuing our relationship with Jazz on these assets in support of further advancement in clinical development,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “The collaboration also illustrates the strength of the Pfenex production platform and the differentiated programs it is able to generate. We look forward to advancing our portfolio and to key milestones that are upcoming in 2018.”

About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company developing complex therapeutic proteins. Using the patented Pfenex Expression Technology® platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company’s lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the US government. In addition, Pfenex is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, the Company’s pipeline includes biosimilar candidates to Lucentis® and Neulasta®.

Pfenex Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements generally relate to future events or Pfenex’s future financial or operating performance.  In some cases, forward-looking statements can be identified because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Pfenex’s expectations, strategy, plans or intentions.  Forward-looking statements in this press release include, but are not limited to, statements regarding Pfenex’s future plans to develop, manufacture and commercialize these product candidates; the potential to receive future milestone and royalty payments under Pfenex’s agreements with Jazz Pharmaceuticals; and Pfenex’s expectations to advance its portfolio and achieve key milestones in 2018 . Actual results may differ materially from those indicated by these forward-looking statements as a result of the uncertainties inherent in the clinical drug development process, including, without limitation, challenges in successfully demonstrating the efficacy and safety of product candidates; the pre-clinical and clinical results for product candidates, which may not support further development of product candidates or may require additional clinical trials or modifications of ongoing clinical trials or regulatory pathways; challenges related to commencement, patient enrollment, completion, and analysis of clinical trials; Pfenex’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives; Pfenex’s dependence on third parties for development, manufacture, marketing, sales and distribution of products; unexpected expenditures; and difficulties in obtaining and maintaining intellectual property protection for product candidates.  Information on these and additional risks, uncertainties, and other information affecting Pfenex’s business and operating results is contained in Pfenex’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 and in Pfenex’s subsequent reports filed with the Securities and Exchange Commission.  The forward-looking statements in this press release are based on information available to Pfenex as of the date hereof, and Pfenex disclaims any obligation to update any forward-looking statements, except as required by law.

Pfenex investors and others should note that Pfenex announces material information to the public about Pfenex through a variety of means, including its website (http://www.pfenex.com/), investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (http://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with its disclosure obligations under Regulation FD.  Pfenex encourages its investors and others to monitor and review the information Pfenex makes public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

$MARK $10 Million Investment from Charoen Pokphan at $12.00 per Share

LAS VEGAS, Dec. 18, 2017 — Remark Holdings, Inc. (NASDAQ: MARK), a global technology company focused on artificial intelligence, today announced a US$10 million investment from Thailand-based Charoen Pokphand Group (CP Group), one of the world’s largest conglomerates.  CP Group’s core businesses span agribusiness and food, retail and distributions, and the telecommunication sectors. Due to CP Group’s exceptional reputation, it was the first foreign company selected to invest in China and is the only one approved to own and operate a TV channel under the Chinese media authority.

In addition to its core businesses, CP Group has significant operating interests in retail, telecommunications and media, e-commerce and digital, property development, plastics, automotive, finance, insurance, and pharmaceuticals.  The company currently operates Southeast Asia’s largest retail business by revenue, with 10,000 7-Eleven stores, and it is one of the largest telecom firms in Southeast Asia with more than 25 million mobile customers. CP Group operates in 30 countries and employs over 700,000 people.

The investment will establish a joint venture partnership between Remark Holdings and CP Group focused on Artificial Intelligence and Data Solutions. The partnership’s first initiative will be to launch an innovative AI Solution and Application for the Real Estate and Commercial Mall sector in Q1 2018.

CP Group Chairman Soopakij Chearavanont stated, “We see tremendous potential in Remark and its KanKan subsidiary, and we look forward to helping the company grow and scale in the future.”

Remark Holdings CEO and Chairman, Kai-Shing Tao said, “We are honored to jointly partner with CP Group and capitalize on the excellent opportunity to expand Remark’s KanKan Artificial Intelligence (AI) and Data Solutions platform and monetize our 1.5 billion current users. There is massive demand in Asia for AI technologies. This investment will help us achieve Asian market penetration and rapidly drive accelerated growth, revenue, and profits.

Through the partnership, CP Group will be able to deploy KanKan’s AI and Data Solutions platform across its vast businesses and investments. This extends to strategic business partners such as CITIC Group, a large, state-owned, multinational conglomerate in China; Ping-An Group, a leading provider of personal financial services in China; and ITOCHU Corp, a large Japanese general trading company. CP Group is the leading shareholder in all of them.

CP Group’s investment is the latest significant development for Remark Holdings as it increases its strategic footprint in Asia. During the past year, it has announced strategic business partnerships with China ShenHua Energy Company and Acxion in China. In 2017, Sina Corporation also released its 3D augmented reality mobile application fully powered by Remark’s 3D facial-feature tracking technology.

About Remark Holdings, Inc.
Remark Holdings, Inc. (NASDAQ: MARK) primarily focuses on the development and deployment of artificial-intelligence-based solutions for businesses and software developers in many industries.  Additionally, the company owns and operates digital media properties that deliver relevant, dynamic content.  The company is headquartered in Las Vegas, Nevada, with additional operations in Los Angeles, California and in Beijing, Shanghai, Chengdu and Hangzhou, China.  For more information, please visit the company’s website at www.remarkholdings.com.

$VLRX to Ring The @Nasdaq Stock Market Closing Bell

ADVISORY, Dec. 18, 2017 —

What:
Valeritas Holdings, Inc. (Nasdaq:VLRX), a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes, with its flagship product, V-Go® Wearable Insulin Delivery Device, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, John Timberlake, President & CEO, will ring the Closing Bell.

Where:
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:
Tuesday, December 19, 2017 – 3:45 p.m. to 4:00 p.m. ET

Valeritas Holdings, Inc. Contact:

Investor Contacts:
Lynn Pieper Lewis or Greg Chodaczek
Gilmartin Group
610-368-6505
ir@valeritas.com

Media Contact:
Kevin Knight
Knight Marketing Communications, Ltd.
(206) 451-4823
pr@valeritas.com

Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/

Webcast:
A live stream of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery Device, is a simple, wearable, basal-bolus insulin delivery device for adults with diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts. For more information, please visit www.valeritas.com.

About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com

$MLNK Announces Acquisition of IWCO Direct for $476 Million in Cash

– Transaction Provides Profitable Growth Platform, Significant Free Cash Flow and Earnings – Steel Partners Holdings to Increase Ownership Stake in ModusLink with $35 Million Investment – Jack L. Howard and William T. Fejes, Jr. Join ModusLink Board of Directors

NEW YORK and WALTHAM, Mass., Dec. 18, 2017 — ModusLink Global Solutions™, Inc. (NASDAQ: MLNK) and Steel Partners Holdings (NYSE: SPLP) today announced that ModusLink has completed the acquisition of privately-held IWCO Direct, a leading provider of data-driven direct marketing solutions, for $476 million in cash.

Warren Lichtenstein, Executive Chairman of ModusLink, said, “We have been looking to acquire a profitable business with attractive operations and financials, and with a strong management team in order to leverage our approximately $2.1 billion in net operating loss carryforwards (NOLs) and cash. We found a great fit in IWCO Direct. We essentially double the size of our Company and add significant earnings and free cash flow. We add a market leader with industry-leading solutions, a client base consisting of Fortune 500 companies, and significant opportunities to drive both top- and bottom-line results. We intend to aggressively grow IWCO Direct, organically and through acquisitions, and will look to leverage Steel Partners’ vast relationships and resources to drive operational excellence and enhance stakeholder value.”

With this transaction completed, IWCO Direct becomes a wholly-owned subsidiary of ModusLink Global Solutions. IWCO Direct will continue to be run by Jim Andersen, who has been CEO since 1999. ModusLink Corporation, the Company’s digital and physical supply chain business, will continue to be run by Jim Henderson.

For the last 12 months through October 2017, IWCO Direct had net revenue of $470.6 million, net income of $18.9 million and Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) of $82.2 million. For the last 12 months through October 2017, ModusLink had net revenue of $417.8 million, a net loss of $22.5 million and negative EBITDA of $3.8 million, although net loss and EBITDA improved by $32.5 million and $28.0 million year-over-year, respectively, as a result of the corporate turnaround plan launched in May 2016. Select financial statements will be included on Form 8-K/A, which will be filed with the Securities and Exchange Commission within 75 days following closing.

IWCO Direct has consistently delivered highly-effective data-driven marketing solutions for its customers, which represent some of the largest and most respected brands in the world. Its full range of services includes strategy, creative and production for multichannel marketing campaigns, along with one of the industry’s most sophisticated postal logistics programs for direct mail. Through its Mail-Gard® product, IWCO Direct also offers business continuity and disaster recovery services to protect against unexpected business interruptions, along with providing print and mail outsourcing services. IWCO Direct is the largest direct mail production provider in North America, with the largest platform of continuous digital print technology and a growing direct marketing agency service. Their solutions enable customers to improve Customer Lifetime Value (CLV), which in turn, has led to increased revenue and longer customer relationships.

“We are excited to join forces with ModusLink,” said Jim Andersen. “Their commitment and expertise, combined with our advanced data-driven marketing solutions, make this new combination advantageous for IWCO Direct’s customers and employees as well as our new shareholders. The future of data-driven direct marketing has never been stronger. The flexibility of becoming part of a global organization will allow us to continue to invest in new technologies and service offerings, further driving value and a greater return on marketing investment for our customers to strengthen their customer relationships and increase revenue.”

Funding for the acquisition of IWCO Direct was provided through cash and debt financing provided by Cerberus Business Finance, LLC, as the Administrative Agent and Collateral Agent, and consists of a term loan in the principal amount of $393.0 million and a borrowing in the amount of up to $25.0 million under a revolving credit facility.

Additionally, it was announced today that Steel Partners Holdings L.P. (NYSE: SPLP) increased its investment in ModusLink through its affiliate SPH Group Holdings, LLC, with a $35.0 million convertible preferred stock investment, which together with its affiliates, brings its beneficial ownership in ModusLink to approximately 52%. Proceeds from the $35.0 million convertible preferred stock investment will be used for working capital and general corporate purposes. The preferred stock transaction was approved by a special committee consisting of independent directors of ModusLink who are not affiliated with Steel Partners.

It was also announced today that Jack L. Howard, President of Steel Partners, and William T. Fejes, Jr., President of Steel Services Ltd., will join the ModusLink board of directors, expanding the board to seven members and filling one existing vacancy.

ModusLink’s advisors on the transactions included the law firms of Ice Miller LLP, Littman Krooks LLP, and Olshan Frome Wolosky LLP, while Stout Advisory served as financial advisor.

About ModusLink Global Solutions, Inc.
ModusLink Global Solutions, Inc. (NASDAQ: MLNK) is a leading global provider of digital and physical supply chain solutions. The Company helps its clients drive growth, lower costs and improve profitability, while simultaneously enhancing the customer experience. With operations supported by 21 sites across North America, Europe, and the Asia-Pacific region, ModusLink partners with the world’s leading brands across a diverse range of industries, including consumer electronics, telecommunications, computing and storage, software and content, consumer packaged goods, retail and luxury, among others. Our solutions and services are designed to help global brands and companies expand their share, across geographies and channels, while continuously improving their end-to-end supply chains. For further details on ModusLink’s solutions visit www.moduslink.com, read the Company’s blog for supply chain professionals, and follow us on LinkedIn, Twitter, Facebook and YouTube.

About IWCO Direct
IWCO Direct (www.iwco.com) is a leading provider of data-driven direct marketing solutions that help clients drive response across all marketing channels to create new and more loyal customers. The company’s full range of services includes strategy, creative, and production for multichannel marketing campaigns, along with one of the industry’s most sophisticated postal logistics strategies for direct mail. Through Mail-Gard®, IWCO Direct also offers business continuity and disaster recovery services to protect against unexpected business interruptions, along with providing print and mail outsourcing services. Learn more by subscribing to IWCO Direct’s SpeakingDIRECT blog, or follow the company on LinkedIn and Twitter.

About Steel Partners
Steel Partners Holdings L.P. (www.steelpartners.com) is a diversified global holding company that owns and operates businesses and has significant interests in leading companies in various industries, including diversified industrial products, energy, defense, supply chain management and logistics, banking and youth sports.

Additional Information about the Preferred Stock
The Preferred Stock will not be and has not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that reflect Steel Partners Holdings’ and ModusLink’s current expectations and projections about their future results, performance, prospects and opportunities. Steel Partners Holdings and ModusLink have tried to identify these forward-looking statements by using words such as “may,” “should,” “expect,” “hope,” “anticipate,” “believe,” “intend,” “plan,” “estimate” and similar expressions. These forward-looking statements are based on information currently available to Steel Partners Holdings and ModusLink and are subject to a number of risks, uncertainties and other factors that could cause their actual results, performance, prospects or opportunities in 2017 and beyond to differ materially from those expressed in, or implied by, these forward-looking statements. These factors include, without limitation, Steel Partners Holdings and ModusLink’s subsidiaries’ need for additional financing and the terms and conditions of any financing that is consummated, their respective customers’ acceptance of their new and existing products, the risk that Steel Partners Holdings or ModusLink or their respective subsidiaries will not be able to compete successfully, the possible volatility of Steel Partners Holdings common or preferred unit prices or ModusLink’s stock price and the potential fluctuation in their respective operating results. Although Steel Partners Holdings and ModusLink believe that the expectations reflected in these forward-looking statements are reasonable and achievable, such statements involve significant risks and uncertainties, and no assurance can be given that the actual results will be consistent with these forward-looking statements. Investors should read carefully the factors described in the “Risk Factors” section of Steel Partners Holdings and ModusLink’s filings with the SEC, including Steel Partners Holdings Form 10-K for the year ended December 31, 2016 and ModusLink’s Form 10-K for the year ended July 31, 2017, and in any interim quarterly reports, for information regarding risk factors that could affect Steel Partners Holdings’ or ModusLink’s results. Except as otherwise required by federal securities laws, neither Steel Partners Holdings nor ModusLink undertakes any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

$OTIV is Developing Bitcoin Capabilities in the Crypto-currency Marketplace

OTI is pursuing the growing Bitcoin market

ROSH PINNA, Israel, Dec. 18, 2017 — On Track Innovations Ltd. (OTI) (NASDAQ: OTIV), a global provider of near field communication (NFC) and cashless payment solutions, has announced that it is developing capabilities to implement the use of Bitcoins in its cashless payment solutions.

Bitcoin usage is growing in the e-payment marketplace, with many establishments accepting online Bitcoins transactions. Bitcoin usage has benefited from a growing acceptance of its ongoing facilitation of transfers. It’s fast becoming the prominent digital Internet transaction currency.

“At OTI we are working hard and intend to rapidly become Bitcoin acceptable in transactions via NFC, Bluetooth or QR code,” stated Shlomi Cohen, OTI’s CEO. “We also look forward to integrating Bitcoin acceptance in our innovative ATM and secure cashless vending products.”

About OTI

On Track Innovations (OTI) is a global leader in the design, manufacture, and sale of secure cashless payment solutions using contactless NFC technology with an extensive patent and IP portfolio. OTI’s field-proven innovations have been deployed around the world to address cashless payment and management requirements for the Internet of Payment Things (IoPT), wearables, automated retail and petroleum markets. OTI distributes and supports its solutions through a global network of regional offices and alliances. OTI is the proud recipient of the 2017 AI Award for Best Cashless Payment Solutions Provider – Israel. For more information, visit www.otiglobal.com.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Whenever we use words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions, we are making forward-looking statements. For example, we are using forward-looking statements when we discuss our development of capabilities to implement Bitcoin acceptance and our intention to become Bitcoin acceptable in transactions via NFC, Bluetooth or QR code. Because such statements deal with future events and are based on OTI’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of OTI could differ materially from those described in or implied by the statements in this press release. Forward-looking statements could be impacted by issues encountered in our development of Bitcoin capabilities, the continued acceptance of Bitcoin as a digital currency, the effects of the protracted evaluation and validation periods in the U.S. and other markets for contactless payment cards, or new and existing products and our ability to execute production on orders, as well as other risks and uncertainties, including those discussed in the “Risk Factors” section and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2016, and in subsequent filings with the Securities and Exchange Commission. Although we believe that the expectations reflected in such forward-looking statements are based on reasonable assumptions, we can give no assurance that our expectations will be achieved. Except as otherwise required by law, OTI disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

OTI Press Contact:
Richard Harris
Marketing Manager
+972-4-686-8004
press@otiglobal.com

$IGC Adjournment of Annual Meeting Voting for Proposals Three and Four to Dec 29

Seeks to Obtain a Quorum of Voting Stockholders Owning Shares as of October 5, 2017

BETHESDA, Md., Dec. 18, 2017 — India Globalization Capital, Inc. (NYSE American:IGC), adjourned again the voting for Proposals Three and Four from its Notice of Annual Meeting of Shareholders, dated October 5, 2017.  Proposal Three seeks approval of the grant of 1,900,000 shares of common stock to be granted from time to time to the Company’s current and new employees, advisors, directors, and consultants by the board of directors, pursuant to certain metrics including performance, vesting and incentive as set by the board of directors and or the CEO; and Proposal Four seeks approval of the issuance of up to 2,000,000 shares of the Company’s common stock to Bricoleur Partners, L.P.

The voting on these two proposals was adjourned to December 29, 2017, to allow the Company’s stockholders additional time to vote. Stockholders who have already voted do not need to recast their votes. Proxies previously submitted in respect of the meeting will be voted at the adjourned meeting unless properly revoked. During the period of the adjournment, the Company will continue to solicit proxies from its stockholders only with respect to the Proposals Three and Four of the Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the annual meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC remain unchanged and can be obtained free of charge at the SEC’s website at www.sec.gov.

The Company encourages all stockholders who have not yet voted to do so before December 29, 2017 at 11:59 p.m., Eastern Standard Time. The stockholders may vote by internet at www.proxyvote.com, or by telephone at 800-454-8683, or by returning a properly executed proxy card to InvestorCom.

Hyalolex and Alzheimer’s:
Alzheimer’s patients suffer from a host of symptoms including anxiety, agitation, and sleep disorders. The hallmarks of Alzheimer’s include plaques, tangles, and dementia. Hyalolex, IGC’s product to treat Alzheimer’s, has been shown to decrease plaques and tangles, control anxiety, and help with sleep disorders thorough a patent-pending pathway.  We expect to bring Hyalolex to market in early 2018, with the hope of bringing much needed relief to Alzheimer’s patients.

IGC has a two-part strategy for commercializing Hyalolex: the FDA long process and the Complementary and Alternative Medicine (CAM), a short path which will allow IGC to distribute Hyalolex through licensed medical cannabis dispensaries in key markets of the U.S., starting with dispensaries in Washington, D.C. and Maryland.

About IGC:
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA.

For more information please visit www.igcinc.us

Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements:
Please see forward-looking statements and risk factors as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact at IGC:  
Claudia Grimaldi
301-983-0998

Contact at InvestorCom, Inc.
Michelle Frosch
877-972-0090

$TIG & Takeda Cx601 Positive CHMP Opinion Crohn’s Disease

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

• First allogeneic stem cell therapy to receive positive CHMP opinion in Europe
• Cx601 offers potential new treatment option for patients who do not respond to current available therapies and are subject to numerous invasive surgeries^[1]

Osaka, Japan, December 15, 2017 and Leuven, Belgium, December 15, 2017, 13:10h CET – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.^[2] This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe.

“Following today’s news, physicians and surgeons in Europe can look forward to offering these Crohn’s disease patients a novel and minimally invasive alternative treatment option in the future, which in clinical trials achieved higher combined remission and lower relapse rates^[*] than the current standard of care,” said Professor Julian Panés, Head of the Gastroenterology Department at the Hospital Clinic of Barcelona (Spain) and President of the European Crohn’s and Colitis Organisation (ECCO). “Perianal fistulas are estimated to affect up to 28% of patients in the first two decades after Crohn’s disease diagnosis and Cx601 offers new hope for those suffering from this severe and debilitating condition.”

Cx601 was assessed by the CAT, the EMA’s specialized scientific committee for Advanced Therapy Medicinal Products (ATMP), such as gene or cell therapies. The positive CHMP opinion was based on results from TiGenix’s Phase III ADMIRE-CD pivotal trial. The ADMIRE-CD trial is a randomized, double-blind, controlled, Phase III trial designed to investigate the efficacy and safety of investigational compound Cx601.^[3] 24-week results were published in The Lancet and showed that Cx601 achieved statistically significant superiority versus the control group in the primary efficacy endpoint of combined remission.^[],1 In addition, the rates and types of treatment related adverse events (non-serious and serious) and number of discontinuations due to adverse events were comparable between Cx601 and control arms, the most common of which were anal abscess and proctalgia.¹ Further follow-up data indicated that Cx601 maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn’s disease over 52 weeks.^[4]

Dr. María Pascual, VP Regulatory Affairs and Corporate Quality at TiGenix, said, “We believe that this first approval recommendation for an allogeneic stem cell therapy in Europe reflects the maturity of our technology and its potential to offer new approaches for difficult to treat conditions. We have worked closely with the EMA and provided a robust data package from a well-designed clinical trial with challenging endpoints. In parallel, we will continue working hard to obtain regulatory approval in the U.S. and to develop Cx601 for additional indications, to fulfil our aim of allowing patients to benefit from the full potential of Cx601 across multiple geographies and diseases.”

The opinion will now be referred to the European Commission with a decision anticipated in the coming months. An MA will allow Cx601 to be marketed in all 28 member states of the EU, plus Norway, Iceland and Lichtenstein.

Cx601 has been licensed to Takeda for the exclusive development and commercialization outside of the U.S. Receipt of the MA will trigger a milestone payment from Takeda to TiGenix of €15 million. The companies have been working closely together to advance preparations for commercialization, with a potential start of the commercial launch by Takeda anticipated after MA is transferred from TiGenix to Takeda.

“Today’s positive CHMP opinion is a crucial step to bringing a new treatment option to patients with complex perianal fistulas in Crohn’s disease,” said Dr. Asit Parikh, Head of Takeda’s Gastroenterology Therapeutic Area Unit. “We would like to thank the scientific community and patients involved in the ADMIRE-CD trial for their support in helping us reach this important milestone. We remain committed to delivering innovative, therapeutic options for patients suffering from gastrointestinal disorders.”

Complex perianal fistulas are considered one of the most disabling complications of Crohn’s disease^[5] and can cause intense pain^[6] and swelling, infection and incontinence.¹ Despite available therapies and surgical advancements, they currently remain challenging for clinicians to treat^[7] and have a significant negative impact on patient quality of life.⁶

Conference call and webcast

TiGenix will conduct a conference call on December 18, 2017 at 15:00 CET / 09:00 ET, which will also be webcast. To participate in the conference call, please call on the following numbers:

Confirmation Code: 9171070

London, United Kingdom:                      +44 20 3427 1900
New York, United States of America:      +1 212 444 0481
Paris, France:                                        +33 1 76 77 2230
Brussels, Belgium:                                +32 2 404 0660
Madrid, Spain:                                      +34 91 114 6582
Amsterdam, Netherlands:                       +31 20 716 8295

The webcast can be followed live online via the link: https://edge.media-server.com/m6/p/o3msgui7

Contacts

For TiGenix:

Claudia Jiménez
Senior Director                                                              Media enquiries:
Investor Relations and Communications                         Consilium Strategic Communications
T: +34 91 804 9264                                                        T: +44 20 3709 5700
claudia.jimenez@tigenix.com                                         tigenix@consilium-comms.com

For Takeda:

Kazumi Kobayashi                                                         Luke Willats
Media in Japan                                                              Media outside of Japan
T: +81 33 278 2095                                                        T: +41 44 555 1145
Kazumi.kobayashi@takeda.com                                    Luke.willats@takeda.com

Takeda’s Commitment to Gastroenterology

Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. Recognizing this unmet need, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years. Takeda aspires to advance how patients manage their disease. Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI research & development team is also exploring solutions in celiac disease, advanced liver disease and microbiome therapies.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

About TiGenix

TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.

TiGenix lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas – a severe, debilitating complication of Crohn’s disease. Cx601 has been filed for regulatory approval in Europe and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas outside the U.S. TiGenix’ second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis – a major cause of mortality in the developed world. Finally, AlloCSC-01, targeting acute ischemic heart disease, has demonstrated positive results in a Phase I/II trial in acute myocardial infarction (AMI). TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain) and Cambridge, MA (USA). For more information, please visit http://www.tigenix.com.

About Cx601

Cx601 is a local administration of allogeneic (or donor derived) expanded adipose-derived stem cells (eASCs) for the treatment of complex perianal fistulas in adult Crohn’s disease patients that have previously shown an inadequate response to at least one conventional therapy or biologic therapy. Crohn’s disease is a chronic inflammatory disease of the intestine and complex perianal fistulas are a severe and debilitating complication for which there is currently no effective treatment. Cx601 was granted orphan drug designation by the European Commission in 2009 and by the U.S Food and Drug Administration (FDA) in 2017. TiGenix completed a European Phase III clinical trial (ADMIRE-CD) in August 2015 in which both the primary endpoint and the safety and efficacy profile were met, with patients receiving Cx601 showing a 44% greater probability of achieving combined remission compared to control (placebo).¹ A follow-up analysis was completed at 52 weeks⁴ and 104 weeks post-treatment, confirming the sustained efficacy and safety profile of the product. The 24-week results of the Phase III ADMIRE-CD trial were published in The Lancet  in July 2016.¹ Based on the positive 24 weeks Phase III study results, TiGenix submitted a Marketing Authorization Application to the European Medicines Agency (EMA). A global Phase III clinical trial (ADMIRE-CD II) intended to support a future U.S. Biologic License Application (BLA) started in 2017, based on a trial protocol that has been agreed with the FDA through a special protocol assessment procedure (SPA) (clinicaltrials.gov; NCT03279081). ADMIRE-CD II is a randomized, double-blind, placebo-controlled study designed to confirm the efficacy and safety of a single administration of Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients. In July 2016, TiGenix entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired exclusive rights to develop and commercialize Cx601 for complex perianal fistulas in Crohn’s patients outside of the U.S.

Forward-looking information
This press release may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company’s control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this press release. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

References

^[*] Relapse defined as reopening of any of the treated external openings with active drainage as clinically assessed, or development of perianal collection >= 2cm of the treated perianal fistula confirmed by centrally blinded pelvic MRI assessment in patients with clinical remission at any previous visit

^[] Combined remission defined as clinical assessment of closure of all treated external openings draining at baseline, despite gentle finger compression, and absence of collections >2cm confirmed by pelvic MRI

^[1] Panés J, García-Olmo D, Van Assche G, et al., Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomized, double-blind controlled trial. The Lancet. 2016; 388(10051): 1281-1290.

^[2] European Medicines Agency. Available at: http://www.ema.europa.eu/ema/. Accessed December 15, 2017.

^[3] Clinicaltrials.gov. Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn’s Disease (ADMIRE-CD). Available at: https://clinicaltrials.gov/ct2/show/NCT01541579?term=cx601 &rank=2. Published February 2012. Accessed December 15, 2017.

^[4] Panés J, García-Olmo D, Van Assche G, et al., Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn’s Disease: 52-week results of a phase III randomized controlled trial. ECCO 2017; Barcelona: Abstract OP009.

^[5] Marzo M, Felice C, Pugliese D, et al., Management of perianal fistulas in Crohn’s disease: An up-to-date review. World J Gastroenterol. 2015; 21(5): 1394-1395.

^[6] Mahadev S, Young JM, Selby W, et al., Quality of life in perianal Crohn’s disease: what do patients consider important? Dis Colon Rectum. 2011; 54(5): 579-585.

^[7] Geltzeiler C, Wieghard N and Tsikitis V. Recent developments in the surgical management of perianal fistula for Crohn’s disease. Ann Gastroenterol. 2014; 27(4): 320-330.

$EGLT Receives FDA Tentative Approval for Expanded Label for ARYMO in Chronic Pain

– Intranasal abuse-deterrent claim to be added to ARYMO ER prescribing information label –

WAYNE, Pa., Dec. 15, 2017 — Egalet Corporation (Nasdaq: EGLT) (Egalet), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for an expanded label for ARYMO ER (morphine sulfate) extended-release (ER) tablets C-II for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The FDA has issued tentative approval for a supplement submitted earlier in 2017 to update the ARYMO ER prescribing information with data from a Category 2/3 intranasal human abuse potential (HAP) study and an intranasal abuse-deterrent claim. This data was previously excluded from the label at original new drug application (NDA) approval due to exclusivity granted to another company. The final approval is expected to be granted when the exclusivity period expires on October 2, 2018.

ARYMO ER, developed using Egalet’s proprietary Guardian™ Technology—a physical and chemical barrier approach to abuse deterrence without the use of an opioid antagonist—creating tablets that are difficult to manipulate for the purpose of misuse and abuse, was approved on January 9, 2017. Results from in vitro testing demonstrated that ARYMO ER tablets, in comparison to non-abuse-deterrent morphine sulfate extended-release (ER) tablets, have increased resistance to cutting, crushing, grinding or breaking using a variety of tools. Due to its physical and chemical properties, ARYMO ER is expected to make abuse by injection difficult.

“Given that extended-release morphine is the most frequently prescribed ER opioid for individuals living with chronic pain and the majority of those prescriptions are in easy to abuse formulations, we believe that strengthening the ARYMO ER label to include additional abuse-deterrent data is an important improvement for chronic pain patients and their communities,” said Mark Strobeck, Ph.D., chief operating officer of Egalet. “While opioids should be reserved for situations when all other alternative therapies have been tried, when opioids are needed, having abuse-deterrent options is important.”

The Category 2/3 intranasal HAP study was conducted in accordance with the FDA Guidance for Industry, Abuse-Deterrent Opioids – Evaluation and Labeling. It was a single-center, randomized, double-blind, double-dummy, active and placebo-controlled, five period crossover study which assessed the abuse potential of ARYMO ER versus MS Contin^® (non-abuse-deterrent morphine sulfate extended-release tablets) in 46 nondependent, recreational opioid users when administered intranasally. The study met its primary endpoint, demonstrating that after insufflation, manipulated ARYMO ER led to significantly (P<0.0001) less drug liking compared with crushed MS Contin. The study also concluded that subjects administered manipulated ARYMO ER intranasally reported a significantly decreased likelihood to take the drug again (P<0.0001) compared with crushed MS Contin. Consistent with these findings, manipulated ARYMO ER demonstrated a similar pharmacokinetic (PK) profile to intact ARYMO ER, whereas crushed MS Contin’s PK profile was consistent with conversion of an opioid from an extended-release to an immediate release absorption profile.

Guardian™ Technology
Egalet’s Guardian Technology has many applications and has been used to develop abuse-deterrent forms of commonly abused prescription medications. Egalet’s proprietary Guardian Technology is a polymer matrix tablet technology that utilizes a novel application of the well characterized manufacturing process of injection molding, which results in tablets that are hard and difficult to manipulate for misuse and abuse. This approach offers the ability to design tablets with controlled-release profiles as well as physical and chemical properties that have been demonstrated to resist both common and rigorous methods of manipulation. Tablets manufactured with Guardian Technology have been shown to have increased resistance to physical methods of manipulation, such as cutting, crushing, grinding or breaking, using a variety of mechanical and electrical tools. They are also resistant to chemical manipulation and attempts at extraction and turn into a viscous hydrogel on contact with liquid, making syringeability very difficult.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO^® ER (morphine sulfate) extended-release tablets for oral use –CII, developed using Egalet’s proprietary Guardian™ Technology, OXAYDO^® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX^® (ketorolac tromethamine) Nasal Spray. Developed using Guardian Technology, Egalet is looking to partner its pipeline of clinical-stage, product candidates including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, including the boxed warning and medication guide, please visit oxaydo.com. For additional information about Egalet, please visit egalet.com.

IMPORTANT SAFETY INFORMATION

ARYMO ER is:

• A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily around-the-clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your pain well enough or you cannot tolerate them.
• A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed you are at risk for opioid addiction, abuse, and misuse that can lead to death.
• Not for use to treat pain that is not around-the-clock.

Important information about ARYMO ER:

• Get emergency help right away if you take too much ARYMO ER (overdose). When you first start taking ARYMO ER, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur.
• Taking ARYMO ER with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.
• Never give anyone else your ARYMO ER. They could die from taking it. Store ARYMO ER away from children and in a safe place to prevent stealing or abuse. Selling or giving away ARYMO ER is against the law.

Do not take ARYMO ER if you have:

• severe asthma, trouble breathing, or other lung problems.
• a bowel blockage or have narrowing of the stomach or intestines.

Before taking ARYMO ER, tell your healthcare provider if you have a history of:

• head injury, seizures
• liver, kidney, thyroid problems
• problems urinating
• pancreas or gallbladder problems
• abuse of street or prescription drugs, alcohol addiction, or mental health problems

Tell your healthcare provider if you are:

• pregnant or planning to become pregnant. Prolonged use of ARYMO ER during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.
• breastfeeding. Not recommended during treatment with ARYMO ER. It may harm your baby.
• taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking ARYMO ER with certain other medicines can cause serious side effects and could lead to death.

When taking ARYMO ER:

• Do not change your dose. Take ARYMO ER exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.
• Take your prescribed dose every 8 to 12 hours, as directed by your healthcare provider. Do not take more than your prescribed dose. If you miss a dose, take your next dose at the usual time.
• Swallow ARYMO ER whole. Do not cut, break, chew, crush, dissolve, snort, or inject ARYMO ER because this may cause you to overdose and die.
• ARYMO ER should be taken one tablet at a time. Do not pre-soak, lick, or wet the tablet before placing in your mouth to avoid choking on the tablet.
• Call your healthcare provider if the dose you are taking does not control your pain.
• Do not stop taking ARYMO ER without talking to your healthcare provider.
• After you stop taking ARYMO ER, flush any unused tablets down the toilet.

While taking ARYMO ER DO NOT:

• Drive or operate heavy machinery, until you know how ARYMO ER affects you. ARYMO ER can make you sleepy, dizzy, or lightheaded.
• Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with ARYMO ER may cause you to overdose and die.

The possible side effects of ARYMO ER are:

• constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.

Get emergency medical help if you have:

• trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.

These are not all the possible side effects of ARYMO ER. Call your doctor for medical advice about side effects.

To report SUSPECTED ADVERSE REACTIONS, contact Egalet US Inc. at 1-800-518-1084 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Safe Harbor
Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature and contain the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “look forward to” and other similar expressions are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the potential impact of strengthening the ARYMO ER label; the success of Egalet’s clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet’s ability to obtain and maintain regulatory approval of Egalet’s products and product candidates and the labeling claims that Egalet believes are necessary or desirable for successful commercialization of its products and product candidates; the impact of strengthening any of the labels for Egalet’s products; Egalet’s ability to maintain the intellectual property position of Egalet’s products and product candidates; Egalet’s ability to identify and reliance upon qualified third parties to manufacture its products; Egalet’s ability to commercialize its products, and to do so successfully; the costs of commercialization activities, including marketing, sales and distribution; the size and growth potential of the markets for Egalet’s products and product candidates, and Egalet’s ability to service those markets; Egalet’s ability to obtain reimbursement and third-party payor contracts for its products; Egalet’s ability to service its debt obligations; Egalet’s ability to raise additional funds to execute its business plan and growth strategy on terms acceptable to Egalet, if at all; Egalet’s ability to find and hire qualified sales professionals; the rate and degree of receptivity in the marketplace and among physicians to Egalet’s products; the success of products that compete with Egalet’s that are or become available; general market conditions; and other risk factors set forth in Egalet’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the United States Securities and Exchange Commission (SEC) and in other filings Egalet makes with the SEC from time to time. While Egalet may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Media and Investor Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: ir@egalet.com
Tel: 484-259-7370

$LFIN Acquires Ziddu.com, A Blockchain-empowered Global Micro-lending Solutions Provider

NEW YORK, Dec. 15, 2017  — Longfin Corp. (NASDAQ: LFIN), a leading global FinTech company, announces the acquisition of Ziddu.com, a Blockchain-empowered solutions provider that offers Microfinance Lending against Collateralized Warehouse Receipts in the form of Ziddu Coins.

Ziddu Coin is a smart contract that enables SME’s, processors, manufacturers, importers and exporters using cryptocurrencies across continents. Ziddu Coins are loosely pegged to Ethereum and Bitcoin. The importers/exporters convert offered Ziddu coins into Ethereum or Bitcoin and use the proceeds for their working capital needs. At the end of the contract, importers/exporters will realize their proceeds and pay back their funds through cryptocurrencies only. Depending upon the risk profile of the counterparty, the interest will vary from 12% to 48%.

“The advent of Blockchain technology has caught the imagination of the global financial services industry; blockchain is emerging as a technological revolution that is set to disrupt the financial services infrastructure. Cryptocurrencies such as Bitcoin and Ethereum will act as a global financing currency to avail credit against hard currencies of many emerging markets.” Says Venkat Meenavalli, Chairman of Longfin Corp.

About Ziddu.com

Ziddu.com is a blockchain-empowered global Micro-lending Solutions Provider. The company provides SEMs with Warehouse financing backed by their commodities in warehouses. Its warehouse financing leverages blockchain technology to finance through Ziddu coins and other cryptocurrencies such as Ethereum and Bitcoin against their collateralized warehouse receipts.

About Longfin Corp.

Longfin (“LFIN”) is a US-based, global FinTech company powered by Artificial Intelligence (AI) and Machine Learning. The company, through its wholly-owned subsidiary, Stampede Tradex Pte. Ltd, delivers foreign exchange and finance solutions to importers/exporters and SMEs. Longfin also provides cryptocurrency-based financial service for importers/exporters with Ziddu coins from its blockchain-empowered subsidiary Ziddu.com. Currently, Longfin has operations in London, Singapore, Dubai, New York, Miami and India.

IR Contact:

Dragon Gate Investment Partners LLC

Tel: +1(646)-801-2803

Email: lfin@dgipl.com

$VSQTF NetworkNewsWire Announces Publication on Blockchain Technology Investment Options

NEW YORK, Dec. 15, 2017 — via NetworkNewsWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Victory Square Technologies, Inc. (CSE:VST) (OTC:VSQTF) (FWB:6F6), a client of NNW and venture builder that creates, funds and empowers entrepreneurs predominantly focused on blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film.

The publication, titled, “Companies Enabling the Blockchain Revolution Offer Diverse Investment Opportunities,” reviews various industry leaders offering innovative blockchain technology solutions.

To view the full publication, visit: https://www.networknewswire.com/companies-enabling-blockchain-revolution-offer-diverse-investment-opportunities/

“Victory Square Technologies, Inc. (CSE:VST) (OTC:VSQTF) (FWB:6F6) recognized early the possibilities of the blockchain for changing transaction tracking by using a distributed network of computers to eliminate the need for third-party auditors. The company, which operates as a venture builder and technology incubator creating, funding and empowering entrepreneurs in a variety of emerging fields, made its first blockchain-related investment approximately three years ago by providing funding and business guidance to the BTL Group, the first publicly traded blockchain company.

“BTL has since developed into a TSX-listed company with a market capitalization in excess of $250 million that provides blockchain solutions to multiple industries with an emphasis on the finance, energy and gaming sectors. The product BTL is best known for, Interbit, is a blockchain platform that makes it possible to rapidly develop business applications designed to boost efficiency. Today some of the largest institutions in the world utilize the Interbit platform to explore the potential of private blockchains.”

About Victory Square Technologies Inc.

Victory Square is a venture builder that creates, funds and empowers entrepreneurs predominantly focused on blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources and other forms of operational support to help them scale internationally. For more information, visit www.VictorySquare.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$AMPE Positive Results Pivotal Phase 3 Trial of Ampion in Severe Osteoarthritis-of-the Knee

– Primary endpoint of OMERACT-OARSI responder rate at 12 weeks achieved statistical significance (p < 0.001) – Ampion™ is the first therapy indicated for signs and symptoms for severe osteoarthritis of the knee and will address a significant treatment gap – Conference call, December 14, at 6:30 a.m. MT (8:30 ET)

ENGLEWOOD, Colo., Dec. 14, 2017 — Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported that the Phase 3 clinical trial of Ampion™ met its primary endpoint with 71% of Ampion™ treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee (p < 0.001). Responders experienced, on average a 53% decrease in pain as measured by WOMAC A and a 50% improvement in function as measured by WOMAC C and a 45% improvement in quality of life as measured by Patient Global Assessment (PGA). In the secondary endpoints, Ampion™ treated patients achieved statistical significance in a composite endpoint of pain and function from baseline in both categories at 12 weeks (p < 0.001), which was supported by an increase in quality of life as measured by patient global assessment (PGA) (p < 0.001). When treated with Ampion™ (n=144), patients experienced significant improvement in a composite endpoint of pain and function compared to all KL 4 saline-treated patients (n=206) in Ampion™ phase 3 clinical trials (p < 0.001).

If approved, Ampion™ would be the first intra-articular injection to treat the signs and symptoms of patients with severe osteoarthritis of the knee (Kellgren-Lawrence x-ray grade 4).  In order to support a label for signs and symptoms, Ampion™ was asked to demonstrate clinical efficacy in a composite response of pain, function and be supported by quality of life.

Ampion™ was well tolerated with treatment-emergent adverse events (TEAEs) comparable to those of placebo in all single-injection studies of Ampion™. There were no drug-related serious TEAEs associated with the Ampion™ arm. The safety and tolerability profile of Ampion™ is consistent with previous studies.  To date, Ampion™ has been given to over 900 patients with no reported drug-related serious TEAEs.

Ampio plans to present a more detailed analysis of the Phase 3 and pooled data at an upcoming scientific meeting as well as submission for publication.

“We are very pleased with the positive Phase 3 data as we believe that Ampion™ will address an unmet medical need, providing severely diseased patients a non-opioid option that not only reduces pain, but also improves function and quality of life in a meaningful way” said Michael Macaluso, Chairman and CEO, Ampio Pharmaceuticals. “We are hopeful that Ampion™ will serve as a safe and effective treatment for an incurable, progressive disease that afflicts 21 million people in the U.S. and over 200 million people worldwide who suffer from osteoarthritis. We look forward to working closely with the U.S. Food and Drug Administration (FDA) as we prepare to submit our Biologics License Application (BLA) for Ampion™.”

In this multi-center, randomized study of 144 KL4 patients with severe OAK of the knee, patients received either a single 4mL intra-articular injection of Ampion™ or placebo at a ratio of 6:1. The primary endpoint of responder analysis using OMERACT-OARSI was evaluated at 12-weeks following a single injection.

The OMERACT-OARSI response composite looks to assess three core symptoms of OAK (pain, function, and patient’s global assessment) as a single variable. For each domain, a response requires both a relative and an absolute change. OMERACT-OARSI response is defined as having a high improvement in pain or function and/or a clinically meaningful improvement in two of three core measurements of OA: pain, function or quality of life. Specifically, to be considered a responder, a patient must demonstrate improvement in WOMAC A (pain) or WOMAC C (function) of ≥50% and absolute change of ≥1.0 point on a 5 point Likert (0-4) scale, or ≥20% improvement in at least 2 of the following 3 categories: WOMAC A, WOMAC C,  or Patient Global Assessment, with a 0.5 point change on a 5 point (0-4) pain scale.

Conference Call
At 8:30 a.m. ET tomorrow, Ampio’s management will host a conference call to discuss the Phase 3 clinical results.  The dial-in number for the conference call is (877) 260-1479 for U.S./Canada participants and (334) 323-0522 for local participants, with Participant Passcode # 6638480. A live webcast of the conference call can also be accessed through the “Investors” tab on the Ampio Pharmaceuticals website at www.ampiopharma.com. A webcast replay will be available online after the call.

About Osteoarthritis
Osteoarthritis (OA) is an incurable and progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone. The incidence of developing osteoarthritis of the knee over a lifetime is approximately 45%. As this disease is associated with age, obesity, and diabetes, this number will continue to grow. Certain risk factors in conjunction with natural wear and tear lead to the breakdown of cartilage. Osteoarthritis is caused by inflammation of the soft tissue and bony structures of the joint, which worsens over time and leads to progressive thinning of articular cartilage. Other symptoms include narrowing of the joint space, synovial membrane thickening, osteophyte formation and increased density of subchondral bone.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward-Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s clinical trials of our Ampion™ product. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Tom Chilcott
Chief Financial Officer
Phone: (720) 437-6500
tchilcott@ampiopharma.com

Media Contact
Chiara Russo
Director, Investor Relations
Lavoie Health Science
Phone: (617) 374-8800 ext. 112
crusso@lavoiehealthscience.com

$SIEB $OSTK Execute Letter of Intent to Offer Discount Trading

SALT LAKE CITY and NEW YORK, Dec. 14, 2017  — Overstock.com (NASDAQ:OSTK), its subsidiary tZERO and Siebert Financial Corp. (NASDAQ:SIEB) have signed a letter of intent to enter into a partnership to offer deeply discounted online trading in Q1, 2018, when the transaction is slated to close. Under terms of the agreement, any investor in America who accesses the Muriel Siebert & Co. Inc. portal at Overstock would be able to conduct online trading of US equities for $2.99 per trade through the platform. In addition, Overstock plans to introduce a new tier to its Club O loyalty and membership rewards program to offer that elite membership level the opportunity for online trading at an even deeper discount of $1.99 per trade.

Overstock and Siebert Financial Corp. intend to deliver institutional quality financial services to clients, enhancing the mutual benefits of this paradigm-changing partnership. New customers subscribing to the discount brokerage suite of products would be offered best-in-class services including Smart Order and Routing and Execution services by tZERO’s broker-dealer Speedroute, a FINRA firm, and Clearing Services through StockCross Financial Services, a FINRA firm and affiliate of Siebert Financial Corp.

For years, millions of consumers have trusted Overstock with home, and more recently, auto purchases. Overstock currently delivers world-class service and award-winning customer experiences to over 30 million shoppers per month, as evidenced by its 2017 Loyalty360 Customer Award in Operational Excellence and its six consecutive Mobile Web Awards for its shopping apps.

Siebert Financial Corp. was founded in 1967 by Muriel Siebert, the first woman to own a seat on the New York Stock Exchange and the first to head one of its member firms, Muriel Siebert & Co., Inc. Ms. Siebert was also a pioneer by transforming her firm into a discount brokerage in 1975 on the first day NYSE members were allowed to negotiate commissions.

Of the newly announced intended deal, Overstock CEO Patrick M. Byrne said, “There are multiple complementary facets of the two companies’ trading ecosystems and today they align perfectly to deliver unmatched value to investors. Mickie Siebert showed that women can make it big on Wall Street, and women have always been an important part of Overstock’s success too, so there is a correlation in our pioneering traditions. Just last week, Overstock and its subsidiary, Medici Ventures, signed the Parity Pledge vowing to empower women into leadership positions. With a significant majority of Overstock’s loyal base being women, it is our distinct honor to partner with a legendary woman-owned firm led by Gloria E. Gebbia. Mrs. Gebbia exemplifies all that is great about the advancement of women in leadership and we are honored to deliver the lowest pricing to our growing user base with such a trusted and iconic partner.”

Gloria E. Gebbia, majority shareholder and board member of Siebert Financial said, “We are pleased to partner with Overstock and its founder Dr. Patrick Byrne, who has been a visionary leader in e-commerce. We continue to uphold the enduring vision and legacy of founder Mickie Siebert with our focus on integrity and the safety of investments, as there is no substitute for understanding the cares and concerns of our clients. Together our efforts will be directed towards delivering quality products and services designed to serve the financial needs of our clients, which will always be our top priority.”

While maintaining the industry’s deepest discounts for online trading, this partnership plans to introduce the rollout of new products and services such as Blockchain Trading, Crypto Products, and Robo Advisory, along with Free IRA products.

Media Contacts:
For Overstock, tZERO and Medici Ventures:
Alexandra Sotiropoulos
+1 212-754-5615
asotiropoulos@intermarket.com

For Siebert Financial Corp.:
LHK Communications, LLC
Laura Hynes-Keller, +1-212-758-8602
laurahk@lhkcommunications.com

About Overstock.com

Overstock.com, Inc. Common Shares (NASDAQ:OSTK) / Series A Preferred (Medici Ventures’ t0 platform: OSTKP) / Series B Preferred (OTCQX:OSTBP) is an online retailer based in Salt Lake City, Utah that sells a broad range of products at low prices, including furniture, décor, rugs, bedding, and home improvement. In addition to home goods, Overstock.com offers a variety of products including jewelry, electronics, apparel, and more, as well as a marketplace providing customers access to hundreds of thousands of products from third-party sellers. Additional stores include Worldstock.com, dedicated to selling artisan-crafted products from around the world. Forbes ranked Overstock in its list of the Top 100 Most Trustworthy Companies in 2014. Overstock regularly posts information about the company and other related matters under Investor Relations on its website, http://www.overstock.com.

About Siebert Financial Corp.

Siebert Financial is a holding company that conducts its retail discount brokerage business through its wholly-owned subsidiary, Muriel Siebert & Co., Inc. The firm became a member of the NYSE in 1967, when Ms. Siebert became the first woman to own a seat on the Exchange. In addition, in 2014 the Company began business as a registered investment advisor through a wholly-owned subsidiary, Siebert Investment Advisors, Inc. Siebert Financial, based on Wall Street in New York City, serves clients through its branch offices located nationwide and globally online. www.siebertnet.com

Cautionary note regarding forward-looking statements

Statements in this press release that are not statements of historical or current fact constitute “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve risks and uncertainties and known and unknown factors that could cause the actual results of the Siebert Financial Corp. (the “Company”) to be materially different from historical results or from any future results expressed or implied by such forward looking statements, including without limitation: changes in general economic and market conditions; changes and prospects for changes in interest rates; fluctuations in volume and prices of securities; changes in demand for brokerage services; competition within and without the brokerage business, including the offer of broader services; competition from electronic discount brokerage firms offering greater discounts on commissions than the Company; the prevalence of a flat fee environment; limited trading opportunities; the method of placing trades by the Company’s customers; computer and telephone system failures; the level of spending by the Company on advertising and promotion; trading errors and the possibility of losses from customer non-payment of amounts due; other increases in expenses and changes in net capital or other regulatory requirements.  As a result of these and other factors, the Company may experience material fluctuations in its operating results on a quarterly or annual basis, which could materially and adversely affect its business, financial condition, operating results, and stock price, as well as other risks detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”).  Accordingly, investors are cautioned not to place undue reliance on any such “forward-looking statements.” The Company undertakes no obligation to update the information contained herein or to publicly announce the result of any revisions to such “forward-looking statements” to reflect future events or developments. An investment in the Company involves various risks, including those mentioned above and those, which are detailed from time to time in the Company’s SEC filings, copies of which may be obtained from the Company or through the SEC’s website.

Notice to Investors

This communication is provided for informational purposes only and is neither an offer to sell nor a solicitation of an offer to buy any securities in the United States or elsewhere.

About Stockcross Financial Services, Inc.

StockCross Financial Services, Inc. is one of the largest privately-owned brokerage firms in the nation. Established in 1971, it has spent many years providing financial guidance and excellent customer service to its clients. Branch offices are located throughout the nation and are staffed with knowledgeable and experienced representatives. Online investment services and phone support offer clients around the world instant and current information on their accounts. StockCross consistently delivers on its full scope of offerings including fixed-income products, online or broker-assisted equity trading, ESOS/ESOP programs across the globe through advanced online trading capabilities, and is a self-clearing firm specializing in fixed income securities, outstanding customer service, and client investment choices. StockCross is headquartered in Beverly Hills. Member FINRA | SIPC | EST. 1971

Specialties

Online Trading, Corporate Services, Fixed Income, Equities, Institutional Trading, Capital Commitment and Market Making, Retail Investment Services.

About Medici Ventures

Launched in 2014, Medici Ventures is a wholly owned subsidiary of Overstock.com, Inc., created to leverage blockchain technology to solve real-world problems with transparent, efficient and secure solutions. Medici Ventures has a growing portfolio of groundbreaking blockchain-focused investments, including t0.com, Peernova, Bitt, SettleMint, Factom, and IdentityMind, Spera and Symbiont. The company’s majority-owned financial technology company, t0.com, executed the world’s first blockchain-based stock offering in December 2016.

About tZERO         

t0.com, Inc. (“tZERO“)  is a majority owned subsidiary of Overstock.com, focusing on the development and commercialization of financial technology (FinTech) based on cryptographically-secured, decentralized ledgers – more commonly known as blockchain technologies. Since its inception, tZERO has pioneered the effort to bring greater efficiency and transparency to capital markets through the integration of blockchain technology. More information is available at tZERO.com.

$OHGI Executes Term Sheet to Acquire 123Wish

LONDON, Dec. 14, 2017 — One Horizon Group, Inc. (NASDAQ:OHGI) today announced that it has entered into a term sheet that includes the main provisions of the definitive agreements to acquire a majority interest in ONCE IN A LIFETIME LLC, d/b/a 123Wish.

123Wish in the Apple App Store and available next month on Google Play and www.123wish.com is a subscription-based, social-media platform that provides users with unique opportunities to enjoy personalized, dream experiences with some of the world’s most renowned influencers, celebrities, professional athletes, fashion designers, and artists while supporting a diverse range of charities.

By way of example, a 123Wish experience includes the chance to star in a Jake Paul YouTube video. Jake Paul’s music video “It’s Everyday Bro featuring Team 10” (Jake’s team of relevant social media influencers) has over 160 million views and frequently released Jake Paul videos reach viewership in the tens of millions.

123Wish was co-founded in early 2016 by real estate mogul and serial technology entrepreneur Andrew Resnick who has developed and launched web properties that reach tens of millions of unique visitors a month and Natalia Diaz whose digital agency MOA Digital Works specializes in mobile and web commerce and gaming development for several Fortune 500 and other innovative company clients that rely on social-media monetization.

Recognizing that fundamental to the 123Wish business model was building relationships with the most influential members of Generation Z, Natalia engaged Gen Z entrepreneur and venture capitalist Patrick Finnegan to harness those relationships and manifest the vision of being an authentic lifestyle brand that Gen Z wanted to embrace.

Patrick brought his partners Jake Paul (more than 12 million YouTube subscribers and more than 10 million Instagram followers) and Cameron Dallas (more than 5 million YouTube subscribers and more than 20 million Instagram followers) and their venture capital fund, TGZ Capital, took a significant equity interest in 123Wish. Their involvement brought immediate momentum to the 123Wish business, which has access to more than 80 million internal and more than 300 million external subscribers and followers.

“Subscribers, fans and likes have become a new form of currency and given the rapid expansion of cryptocurrency, we see a world where social media platform-based commerce and even charitable contribution will be driven by digital coins that allow for efficient and transparent transactions,” said 123Wish Co-Founder Andrew Resnick. “Using coins as a vehicle for transfers of funds affords unique opportunities to educate the next generations about contributing to the greater good and social media is the perfect outlet to expand and support these systems.”

“While the agreement is subject to customary conditions including completion of due diligence and approvals, we expect to close in the first quarter of 2018 and we are confident the acquisition will be accretive in 2018,” said One Horizon Group’s Founder and CEO, Mark White. “We are excited to be working with the 123Wish team and we are certain that this transaction will deliver significant value to OHGI shareholders.”

Each curated 123Wish experience supports a philanthropic cause of the celebrity or influencer’s choosing or is randomly matched to a non-profit. Once the charitable contribution goal for an experience has been met and the timeframe for entry has expired, 123Wish randomly selects the winner. Subscribers have exclusive opportunities to interact with experience contributors and everyone who enters receives a specialized gift for participating. Corporate sponsors of the experiences include some of the world’s most widely recognized brands that seek to connect with 123Wish subscribers and are aligned with the celebrity or influencer’s desire to make a positive social impact.

“Social media influencers and celebrities are building brands with unprecedented reach given their ability to connect with their subscribers and fans on an emotional level,” said 123Wish Co-Founder and CEO Natalia Diaz. “As I described in speaking with Forbes earlier this year, working with influencers gives advertisers the ability to more specifically address their target demographic as compared with traditional forms of advertising. In order to expand the reach of 123Wish and to give investors an opportunity to participate in the next wave of social media that speaks to Gen-Zers and Millennials who place a higher value on human experiences that contribute to the greater good than high-cost material items, we welcome the desire of One Horizon Group to allow us to further build our business as part of a NASDAQ-listed technology company.”

“In founding 123Wish, Natalia and I recognized that through our close friends and business contacts, we have access to some of the world’s most popular social media influencers, celebrities, professional athletes, fashion designers, and artists,” added 123Wish Co-Founder Andrew Resnick. “We also realized that what attracted us to these people was a fundamental desire to contribute our talents to make the world a better place for everyone. 123Wish not only provides subscribers with the possibility of participating in one-of-a-kind experiences; the company has created an engaging community of talent and fans collaborating to take significant and lasting action on social issues. After spending time with One Horizon Group’s Founder and CEO Mark White, we realized that our companies are philosophically aligned and that by combining our strengths, we will be able to build a stronger organizational foundation, expand our reach even further, and importantly, make a greater social impact for good.”

About One Horizon Group, Inc.

One Horizon Group, Inc. (NASDAQ:OHGI) is a reseller of secure messaging software for the growing gaming, security and education markets including in China and Hong Kong.  For more information on the Company please visit http://www.onehorizongroup.com/investors-overview/.

Darrow Associates Contacts for OHGI

Bernie Kilkelly
(516) 236-7007
bkilkelly@darrowir.com

Jordan Darrow
(512) 551-9296 
jdarrow@darrowir.com

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8)

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) is a venture builder that creates, funds and empowers entrepreneurs working in the fields of blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources, and other forms of operational support to help them scale internationally.

Victory Square has made multiple early partnerships and investments in the blockchain space. Approximately three years ago the company incubated and invested in BTL Group, which is now a $150 million dollar TSX-listed company offering blockchain solutions across multiple industries with particular focus on the finance, energy and gaming sectors. BTL’s showcase product – Interbit – is a blockchain platform that facilitates the rapid development of business applications that dramatically improve efficiency. Some of the world’s largest institutions are using Interbit to explore new opportunities on private blockchains.

A new social sports betting platform to be developed by Victory Square’s wholly owned subsidiary, FansUnite Media Inc. As a social sports data platform, FansUnite relies on robust data to allow members of its community to engage with like-minded individuals by collaborating, discussing, and predicting the winners of sporting events with a free virtual currency. The integration of blockchain technology into FansUnite’s social sports data platform could also lead to blockchain initiatives developed by other divisions and subsidiaries of Victory Square.

Integral to the FansUnite platform is the introduction of FAN Tokens, an in-game currency purchased with the cryptocurrency Ethereum that token holders can use to place wagers. FansUnite members will be able to earn FAN Tokens through participation in any number of networking effects identified in the company’s Bounty program.

“Blockchain technology and the inherent security it provides will enable us to push every envelope we can to build the most dynamic and responsive social sports betting platform,” said Darius Eghdami, Co-Founder and Chief Executive Officer of FansUnite. “The opportunity to secure data through Blockchain certainly appeals to the accountant in me and we are confident it will become the gold standard among sports betting sites around the world.”

Company subsidiary Victory Square Health Inc., which serves as the venture arm dedicated to companies focused on the development of solutions in personalized health technologies, has also invested in Personalized Biomarkers Inc. (PBI). PBI develops test kits that reliably predict the expected response to a number of therapies prior to prescription, with an initial focus on diabetes. Within this field, five potential biomarkers have been identified, allowing PBI to enter a $4 billion market opportunity.

“We are excited for the opportunity to partner with Personalized Biomarkers as they have correctly identified a massive market opportunity, and have formed an exceptional team of industry leaders,” said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. “This is another investment that is fully aligned with our newly created subsidiary, and one we expect to significantly impact the landscape of personalized medicine.”

A partnership with Insight Diagnostics Inc., also through Victory Square Health, will focus on the development of a personalized diagnostic solution for the improved management and prevention of Type II diabetes.

The company’s investment in V2 Games, a development and publishing studio of high-quality mobile games, is another example of incubating great ideas. V2 Games is well known for its successful launch of PAC-MAN Bounce and Beast Brawlers, two of the company’s releases that are capturing the gaming world by the millions of downloads.

In a move designed to strengthen its presence in film and entertainment, Victory Square has acquired a 40 percent equity stake in United Film Fund II, LLC, which is producing three major motion pictures in 2017 and 2018 including “What They Had,” starring two-time Academy Award winner Hilary Swank.

“This kind of investment in entertainment and film represents a major plank for our Company going forward and we consider ourselves fortunate to have the opportunity to acquire this 40% stake in the Film Fund,” said Tejani, who has launched more than 40 startups in 21 countries that employ hundreds of people and generate more than $100 million in annual revenues. “We believe it’s another strong initiative in film production for us and our stakeholders,” he added.

Victory Square has strategically positioned itself in the legal cannabis industry through an investment in Tantalus Labs, a Canadian-based cannabis cultivation company. Tantalus Labs optimizes plant health and sustainable cultivation by using a unique, environmentally controlled greenhouse engineered specifically for growing cannabis. Called a “SunLab,” the greenhouse takes 90 percent less electricity, uses filtered rainwater, and cools the growing environment to prevent stagnant moisture, recycling the air every 7 minutes to achieve maximum airflow.

Victory Square and its leadership team have seamlessly transitioned from its former identity as Fantasy 6 Sports Inc, a company focused solely on fantasy sports, mobile gaming and immersive sports, to a strategic technology company that creates, funds and successfully executes leading-edge ideas. A long-time technology entrepreneur and advocate of the industry, Tejani received the Person-of-the-Year Award at the 2017 Technology Impact Awards in British Columbia, a hallmark award category that recognizes betterment of the tech industry through leadership and philanthropic or enterprise skills and talents. Tejani has pledged to match up to $1 million in donated funds to be shared by a number of Canadian endeavors aimed at education and child-safe projects.

“These are exciting and important steps in the evolution and growth of our Company, and which properly and fully align with our strategic plan focusing on our core competencies in Blockchain Technology, Artificial Intelligence, Gaming, Personalized Health, Film and Virtual, Augmented and Mixed Reality,” said Tejani. “We’re spurred on by the success we have had in building on our original forays into fantasy sports, mobile gaming and immersive sports. In addition, we are energized by our most recent initiatives in sports, personalized health and entertainment and the confidence being shown by our shareholders in the dynamic direction of the Company.”

Victory Square Technologies and its management team believe innovation, incubation of excellent ideas and social responsibility are at the core of its growing success.

Investment Considerations

• Venture incubator for VR/AR entrepreneurs, blockchain technology, artificial intelligence, personalized health, gaming and film
• Subsidiary is developing social sports betting platform utilizing blockchain technology
• Virtual reality (VR) and augmented reality (AR) applications span countless industries
• With 5 billion mobile devices worldwide, mobile gaming market is a multibillion industry

$IGC Update on Hyalolex for Alzheimer’s Commercialization Strategy

BETHESDA, Md., Dec. 14, 2017 — India Globalization Capital, Inc. (NYSE American:IGC) today provides an update on corporate initiatives to launch its lead product for Alzheimer’s, Hyalolex, through licensed medical dispensaries in the U.S.  Investors and interested parties are encouraged to visit www.Hyalolex.com for information on Alzheimer’s disease and research data related to our product formulation.

Hyalolex Liquid Formulation

As previously reported, IGC has a two-part strategy for commercializing its lead product, Hyalolex.  It is anticipated, subject to adequate funding, to move the Alzheimer’s formulation through FDA registered pre-clinical and clinical trials.  Independent of the FDA process, IGC expects to license its formulation technology for distribution as a Complimentary and Alternative Medicine (CAM) through licensed medical cannabis dispensaries in key markets of the U.S.  This process will include state-by-state sourcing, formula assembly, packaging and distribution utilizing best practices to ensure quality control while complying with the current legal guidelines established by each individual state in which Hyalolex is sold.  Medical cannabis is currently legal in 29 states and in Washington, D.C.

Early 2018 Initial Rollout / Marketing Program

IGC has identified dispensaries in Washington, D.C. and Maryland as initial distribution sites to launch the product once final inventory is secured.  This is expected to occur in early 2018 with subsequent expansion into additional U.S. states dependent on product procurement and associated compliance achievement.  In anticipation of this, IGC has retained The Medical Marketing Group, Inc., a provider of outsourced product-detailing, education and outreach services to assist with the Company’s national dispensary expansion ambitions.

Alzheimer’s patients suffer from a host of symptoms including anxiety, agitation, and sleep disorders. The hallmarks of Alzheimer’s include plaques, tangles, and dementia. Hyalolex has been shown to decrease plaques and tangles, control anxiety, and help with sleep disorders thorough a patent-pending pathway.  Based on these and other studies, we expect to bring Hyalolex to market in early 2018, with the hope of bringing much needed relief to Alzheimer’s patients.

About IGC

The Company has two lines of businesses: a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients.  It is also engaged in the development of cannabis based combination therapies to treat pain, nausea, eating disorders, several endpoints of Parkinson’s, and epilepsy in dogs and cats.  The company is based in Maryland, USA.

For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements

Please see forward-looking statements and risk factors as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact
Claudia Grimaldi
301-983-0998

$VSQTF Taps Guy Halford-Thompson to Accelerate Growth of Its Blockchain Portfolio

VANCOUVER, British Columbia, Dec. 14, 2017 — Victory Square Technologies Inc. (“Victory Square” or the “Company“) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce the appointment of Guy Halford-Thompson, co-founder of BTL Group (TSX-V:BTL) (OTC:BTLLF) to its Advisory Board. Mr. Halford-Thompson is a globally recognized pioneer and visionary in blockchain technology and will play a key role in growing and scaling Victory Square’s current portfolio of blockchain companies.

Victory Square has been a long-time supporter of Halford-Thompson’s vision for incorporating blockchain technology into enterprise business, having invested in and incubated his company, the BTL Group three years ago. BTL Group was the first publicly traded blockchain company in Canada and has grown to a market cap of $250M on the TSX Venture Exchange. The product BTL is best known for, Interbit, a blockchain development platform that leverages cutting edge tools to empower developers to build enterprise-grade blockchain-based applications. BTL has partnered with large institutions like Visa and BP to further explore the potential for private blockchains to reduce cost and increase efficiency.

“Guy has been a thought-leader in the blockchain space for years and has had tremendous success building one of Canada’s premier blockchain companies, the BTL Group,” said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. “We are extremely excited and fortunate to have him join Victory Square due to his extraordinary vision and foresight on how blockchain will disrupt verticals that our portfolio companies operate in, such as Gaming, Health, Fintech, VR/AR/MR, and AI.”

Mr. Halford-Thompson will immediately begin advising VST portfolio companies Blockchain Assembly and FansUnite grow and scale their businesses, and will play a strategic role in Victory Square’s new partnership with the Blockchain Investment Consortium to identify the most promising and disruptive blockchain companies around the world.

“Victory Square played a key part helping BTL scale in its early days, and I’m extremely excited to join the team as an advisor,” said Mr. Halford-Thompson. “The leadership group at Victory Square has consistently shown an ability to identify large market opportunities, as well as the right teams to capitalize on them. They give them the funding, resources and relationships required to accelerate their growth and allow them to scale internationally.”

For further information about the Company, please contact:
Howard Blank, Director
Email: ir@victorysquare.com
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square is a venture builder that creates, funds and empowers entrepreneurs predominantly focused on Blockchain Technology, Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources and other forms of operational support to help them scale internationally. For more information, please visit www.victorysquare.com.

FORWARD-LOOKING INFORMATION
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Victory Square. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including future plans. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Victory Square can give no assurance that they will prove to be correct. Forward- looking statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether because of new information, future events or results or otherwise, other than as required by applicable securities laws.

$LTEA Announces Partnership with European Cold-Pressed Juice Company Natur

– Long Island Iced Tea to Distribute Natur Brands in the Americas and Natur to Distribute Long Island Iced Tea Brands in Europe –

– Provides Long Island Iced Tea and Natur with Global Reach for their Complementary Products to Construct Diversified ‘Better-For-You’ Consumer Portfolio –

Farmingdale (Long Island), NY, Dec. 13, 2017 — Long Island Iced Tea Corp. (NasdaqCM: LTEA) (the “Company”), a growth-oriented company focused on the ready-to-drink (“RTD”) tea segment in the beverage industry, today announced the signing of two distribution agreements with Natur, a European hi-tech healthy food and beverage company. The Company will be the exclusive distributor of Natur’s branded products in North and South America, and Natur will be the exclusive distributor of the Company’s branded products in Europe.

The first of Natur’s products that the Company will begin to distribute is its Super Not-From-Concentrate (“SNFC”) line of juices, available in 250ml and 750ml bottle sizes. The SNFC juices are differentiated in their shelf life (31 days ambient and 180 days chilled) as well as their nutritional density from extracting high levels of nutrients from fruits or vegetables, all while maintaining a premium quality and taste. More information about Natur and its innovative product offerings is available at https://int.natur.eu.

Philip Thomas, Chief Executive Officer of the Company, commented, “We are very excited with the opportunity to distribute Natur’s hi-tech, better-for-you brands in North and South America. Its brands are supported by ‘farm-to-shelf’ traceability, and the company has access to outstanding research and development via its shareholder AMC.”

Robert Jan van Olm, Chief Executive Officer of Natur, added, “Long Island Iced Tea is a great partner for us in the US, having established an extensive distribution footprint across the Northeast of the US as well as emerging positions in Canada and Latin America. We believe their existing distribution position, underpinned by our effective e-commerce platforms which we will roll out and support in the US, will combine to create exciting growth opportunities. Reciprocal to this, we expect Natur to deliver similar benefits for the Long Island Tea brands in Europe.”

About Long Island Iced Tea Corp.

Headquartered in Long Island, NY, Long Island Iced Tea Corp. operates in the non-alcohol, ready-to-drink segment of the beverage industry. The Company’s flagship brand ‘The Original Long Island Brand Iced Tea^®’, together with ‘The Original Long Island Brand Lemonade^TM’ are marketed as premium beverages made with non-GMO ingredients. The company also imports and markets ‘ALO Juice^®’ a functional Aloe Vera based beverage. The Company’s portfolio of premium brands sits within the ‘better-for-you’ category of the beverage industry, and are offered to consumers at an affordable price, reflecting the Company’s mission.  Its beverages are sold primarily through a network of regional chains and distributors, primarily on the East Coast and the Midwest of the United States, as well as Canada and Latin America. The Company’s website is www.longislandicedtea.com.

About Natur 

Natur is Europe’s first hi-tech health food & beverage company with a mission to revolutionize natural juice and snack consumption, allowing consumers to afford a better quality of life through natural and functional nutrition.  Natur offers 100% natural / organic juices and snacks with no additives, preservatives, and all are non-GMO.  Their focus is on the premium branded segment in which consumers are increasingly moving towards healthier alternatives, embracing the ‘snackification’ trend. Natur has a multi-channel route to market via leading retailers, foodservice partners, online subscription models and through to its own European flagship retail stores.

The company utilises novel production technologies, such as cold-pressed / HPP, and, Super-NFC (‘not-from-concentrate’) enabling them to offer uniquely competitive products with extended shelf life, while retaining their organoleptic properties. Natur’s cold pressed, raw juice portfolio benefits from a 31 days shelf life, while the Company’s Super-NFC nutrient dense and functional juice products have a shelf life of up to 6 months. Further, the Super-NFC brands allow for ambient transportation up to four weeks opening the doors to global export markets. The Company has forged a strategic partnership with one of its key shareholders, the AMC Group, a global leader of private label juice (with annual revenues exceeding $1.2B), which owns and controls its entire production and supply chain, allowing Natur to offer a truly holistic ‘farm to fridge’ experience.

Forward Looking Statements 

This press release includes statements of the Company’s expectations, intentions, plans and beliefs that constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to come within the safe harbor protection provided by those sections. These statements, which involve risks and uncertainties, relate to the discussion of the Company’s business strategies and its expectations concerning future operations, margins, sales, new products and brands, potential joint ventures, potential acquisitions, expenses, profitability, liquidity and capital resources and to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable. These statements include any statement that does not directly relate to a historical or current fact. You can also identify these and other forward-looking statements by the use of such words as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “thinks,” “estimates,” “seeks,” “predicts,” “could,” “projects,” “potential” and other similar terms and phrases, including references to assumptions. These forward looking statements are made based on expectations and beliefs concerning future events affecting the Company and are subject to uncertainties, risks and factors relating to its operations and business environments, all of which are difficult to predict and many of which are beyond its control, that could cause its actual results to differ materially from those matters expressed or implied by these forward looking statements. These risks include possible accounting adjustments made in the process of finalizing reported financial results, the Company’s history of losses and expectation of further losses, its ability to expand its operations in both new and existing markets, its ability to develop or acquire new brands, its relationships with distributors, the success of its marketing activities, the effect of competition in its industry and economic and political conditions generally, including the current economic environment and markets. More information about these and other factors are described in the reports the Company files with the Securities and Exchange Commission, including but not limited to the discussions contained under the caption “Risk Factors.” When considering these forward looking statements, you should keep in mind the cautionary statements in this press release and the reports the Company files with the Securities and Exchange Commission. New risks and uncertainties arise from time to time, and the Company cannot predict those events or how they may affect it. The Company assumes no obligation to update any forward looking statements after the date of this press release as a result of new information, future events or developments, except as required by the federal securities laws.

Contacts:

For Long Island Iced Tea Corp.                                                                                      

Phil Thomas

1-855-542-2832

info@longislandteas.com

For Natur

Robert Jan van Olm 
pr@natur.eu

$WPRT 2018 Emissions Certifications for L9N and B6.7N Natural Gas Engines

VANCOUVER, British Columbia, Dec. 13, 2017  — Cummins Westport Inc. (“CWI”) announced today that it has received certifications from both the U.S. Environmental Protection Agency (“EPA”) and Air Resources Board (“ARB”) in California for its 2018 L9N and B6.7N natural gas engines. Both engines meet California ARB optional Low NOx standards, as well as 2017 EPA greenhouse gas emission (“GHG”) requirements, making them some of the cleanest engines available today for truck and bus customers.

The L9N is certified to Californial ARB optional Low NOx standard of 0.02 g/bhp-hr ‒ a 90% reduction from engines operating at the current EPA NOx limit of 0.2 g/bhp-hr. The L9N offers ratings from 250 – 320 hp and 1,000 lb-ft peak torque, making it ideal for transit, shuttle and school bus, as well as medium-duty truck and refuse applications.

The B6.7N is certified to California ARB optional Low NOx standard of 0.1 g/bhp-hr – a 50% reduction from current EPA levels. Available with ratings from 200 – 240 hp and 560 lb-ft peak torque, the B6.7N is a great fit for school bus, shuttle, and medium-duty truck applications.

Based on the ISL G and ISB6.7 G natural gas engines, the 2018 L9N and B6.7N build on the experience gained from over 80,000 Cummins Westport engines currently in service and provide a present-day solution to urban air quality issues. In addition to ultra low emissions, the L9N and B6.7N feature a new engine control module with improved durability, on-board diagnostic (“OBD”) capability, an enhanced maintenance-free three-way catalyst, and a closed crankcase ventilation system.

“Cummins Westport is proud to offer emissions-leading products for our truck and bus customers,” said Rob Neitzke, President of Cummins Westport. “The L9N and B6.7N engines offer customers reliability and performance with near-zero emissions today. Natural gas engines are a mature technology, and are supported by an established fueling and supply infrastructure, enabling fleets to incorporate near-zero emissions technology into their fleets. Cummins Westport’s new 2018 products mean our customers can choose the most affordable path to zero-equivalent emissions with no commercial constraints on supply or technology readiness.”

All CWI engines offer customers the choice of using compressed natural gas (“CNG”), liquefied natural gas (“LNG”), or renewable natural gas (“RNG”) as a fuel. RNG is pipeline-quality natural gas produced from the decomposition of organic waste, which can come from a variety of sources such as dairy farms, landfills, and urban waste treatment plants. Combining Cummins Westport’s ultra low emission engines with RNG fuel provides additional and significant GHG reductions.

For 2018, the L9N and B6.7N will be available as a first-fit option from leading bus and truck manufacturers. Cummins Westport will also introduce the ISX12N natural gas engine as a first-fit option, which like the L9N, will meet the Optional Low NOx emissions level of 0.02 g/bhp-hr. Production of all three engines will begin in the first quarter of 2018.

CWI would like to acknowledge engine development funding support from the Gas Technology Institute, South Coast Air Quality Management District, SoCalGas, and the California Energy Commission.

About Cummins Westport Inc.

Cummins Westport Inc. designs, engineers and markets 6-12 liter spark-ignited natural gas engines for North American commercial transportation applications such as trucks and buses.  Cummins Westport is a joint venture of Cummins Inc. (NYSE:CMI), a corporation of complementary business units that design, manufacture, distribute and service engines and related technologies, including fuel systems, controls, air handling, filtration, emission solutions and electrical power generation systems, and Westport Fuel Systems Inc. (NASDAQ:WPRT) (TSX:WPRT), a global leader in alternative fuel, low-emissions technologies that allow engines to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas (LNG), hydrogen, and biofuels such as landfill gas. www.cumminswestport.com

Inquiries: 

Westport Fuel Systems Inc.
Caroline Sawamoto
Manager, Investor Relations & Communications
Phone: 604-718-2046
Email: invest@wfsinc.com
Web: www.wfsinc.com

Cummins Inc.
Jon Mills
Director – External Communications
Phone: 317-610-4244
Email: jon.mills@cummins.com
Web: www.cummins.com

$OSTK de Soto and Byrne Unite to Challenge Global Poverty & Inequality

Blockchain used to Create First Global Record of Who Controls Territory and Property Rights

SALT LAKE CITY, Dec. 13, 2017 — World-renowned economist Hernando de Soto and blockchain technology leader Patrick Byrne (founder Overstock.com, Inc. (NASDAQ:OSTK) and blockchain subsidiary Medici Ventures) have formed a joint venture to develop a global property registry system to surface  the property rights of billions of people in the developing world. The new company – De Soto, Inc. – brings together de Soto’s decades worth of reforms (especially regarding property rights) at the Institute for Liberty and Democracy (ILD) and Medici Ventures’ blockchain expertise to build solutions to empower individuals through recognized property ownership.

De Soto, Inc. is developing a blockchain-based system using mobile applications and social media integration that will bring to light the thousands of “disconnected ledgers” (i.e., informal ownership records) that exist at local levels in communities around the world. In doing so, it will create a global repository on which ownership and transfer can be based. The system aims to promote the interests of people who are currently operating extra-legally, as well as multinational corporations who are trying to cooperate with local owners. The company expects to launch its first pilot program in early 2018.

“I envision a world in which people with rights to their property and business assets pull themselves—and their communities —out of poverty,” said de Soto. “About 80 percent of the world’s population is unable to enter into the modern global economy due to lack of visible and standardized property records. Billions of people have resources that cannot easily be transformed into productive capital. Blockchain is a powerful tool to solve these structural issues, which are some of the principal causes of poverty and conflict.”

Considering merely real estate, the poor in developing countries own a staggering $14 trillion in assets that is “dead capital.” In Peru alone, untitled real estate assets amount to $74 billion in value that Peruvians cannot use to establish creditworthiness or leverage as collateral for loans. Lacking formal ownership and the legal protection it affords, citizens of the developing world may turn for protection to terrorist organizations, who gain power by promising enforcement of de facto local property ownership.

Byrne, CEO of Overstock.com and founder of its subsidiary Medici Ventures, has been a longtime advocate for bitcoin and its underlying technology, blockchain. “Working with Hernando de Soto is the honor of my lifetime,” said Byrne. “Hernando’s work has demonstrated that secure ownership of property is a catalyst that sets into motion the engine of progress, creating enormous wealth in the process. From my first public talks on blockchain I emphasized that blockchain’s application to property could lift billions out of poverty. Hernando and I intend to use blockchain technology to empower and enfranchise the five billion people who live outside formal economies within five years.”

“One of our main missions is to democratize capital – to help the poorest members of society participate in global markets,” said Jonathan Johnson, president of Medici Ventures. “Hernando’s work proves that implementing policies to surface and protect property rights undermines terrorist organizations and promotes the prosperity of those who were previously forced to operate outside the formal economic system. Blockchain can solve this problem. It’s great to be partnering with Hernando to bring this vision to reality.”

De Soto is founder and president of the Peru-based Institute for Liberty and Democracy, considered by The Economist to be one of the two most important think tanks in the world. In the last 30 years, de Soto has been designing and implementing legal reforms to empower the poor in Africa, Asia, Latin America, the Middle East, and former Soviet nations through programs that grant access to formal property rights.  De Soto has been written of as “One of the 12 Most Important Economists in the World ”. He  won the prestigious Milton Friedman Prize in 2005, was listed as one of 15 innovators “who will reinvent your future” according to Forbes magazine’s 85th anniversary edition, and has been described by Bill Clinton as “the world’s most important living economist”.

Byrne is the founder/CEO of Overstock.com. Wired Magazine has called Byrne, “The Messiah of Bitcoin”. Byrne has been named the National Entrepreneur of the Year (Ernst & Young, 2011). Overstock has been voted #9 in Employees Choice “Best Places to Work” (Glassdoor, 2011) and named one of the “100 Most Trustworthy Companies in America” (Forbes, 2014).

About Medici Ventures:
Launched in 2014, Medici Ventures is a wholly owned subsidiary of Overstock.com, Inc., created to leverage blockchain technology to solve real-world problems with transparent, efficient and secure solutions. Medici Ventures has a growing portfolio of groundbreaking blockchain-focused investments, including t0.com, Peernova, Bitt, SettleMint, Factom, and IdentityMind, Spera and Symbiont. The company’s majority-owned financial technology company, t0.com, executed the world’s first blockchain-based stock offering in December 2016.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include all statements other than statements of historical fact. Additional information regarding factors that could materially affect results and the accuracy of the forward-looking statements contained herein may be found in the Company’s Form 10-Q for the quarter ended September 30, 2017, which was filed with the SEC on November 8, 2017, and any subsequent filings with the SEC.

About Overstock.com
Overstock.com, Inc. Common Shares (NASDAQ:OSTK) / Series A Preferred (Medici Ventures’ tZERO platform: OSTKP) / Series B Preferred (OTCQX:OSTBP) is an online retailer based in Salt Lake City, Utah that sells a broad range of products at low prices, including furniture, décor, rugs, bedding, and home improvement. In addition to home goods, Overstock.com offers a variety of products including jewelry, electronics, apparel, and more, as well as a marketplace providing customers access to hundreds of thousands of products from third-party sellers. Additional stores include Pet Adoptions and Worldstock.com dedicated to selling artisan-crafted products from around the world. Forbes ranked Overstock in its list of the Top 100 Most Trustworthy Companies in 2014. Overstock regularly posts information about the company and other related matters under Investor Relations on its website, http://www.overstock.com.

O, Overstock.com, O.com, Club O, Main Street Revolution, and Worldstock are registered trademarks of Overstock.com, Inc. O.biz and Space Shift are also trademarks of Overstock.com, Inc. Other service marks, trademarks and trade names which may be referred to herein are the property of their respective owners.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements include all statements other than statements of historical fact. Additional information regarding factors that could materially affect results and the accuracy of the forward-looking statements contained herein may be found in the Company’s Form 10-Q for the quarter ended September 30, 2017, which was filed with the SEC on November 8, 2017, and any subsequent filings with the SEC.

SOURCE: Overstock.com, Inc.

Media Contact:
pr@mediciventures.com

$DPW Creates Cryptocurrency Mining Division

Company Signs Agreement to Develop and Manage Digital Mining Farms Worldwide

FREMONT, Calif., Dec. 13, 2017  — Digital Power Corporation (NYSE American:DPW) (“Digital Power” or the “Company“), a company seeking to increase revenues through acquisitions and organic growth, announced today that it has launched a new business division dedicated to the mining of cryptocurrencies. The Company’s initial strategy is to mine the top ten cryptocurrencies including Bitcoin (“BTC”), Ethereum (“ETH”), Bitcoin Cash (“BCH”), Litecoin (“LTC”), Dash (“Dash”) and Monero (“XMR”). To lead the launch and development of the cryptocurrency mining endeavors, the Company has entered a management services agreement with IMG Networks (“IMG”) of San Diego to establish a series of digital mining farms worldwide with a goal of developing a network of over 10,000 digital mining machines.

Digital Power emphasized that its decision to pursue digital mining of cryptocurrencies and establish the new business division was reached through a series of evaluations, research and actions undertaken by the Company and by PoW Digital Mining, the independent consultants contracted by the Company to lead its development of its cryptocurrency endeavors, as previously announced in a press release dated August 10, 2017. Since September 2017, Digital Power and PoW Digital Mining tested an array of digital mining equipment in its efforts to identify initiatives the Company should pursue and lay the basis of their priority. With the Company’s recent decision to create a cryptocurrency mining division, the testing complex has been transitioned to the commercial generation of revenue. Given the recent approval of Bitcoin to be publicly-traded over two U.S. national exchanges (Chicago Board Options Exchange (“CBOE”) Futures Exchange (“CFE”) and Chicago Mercantile Exchange) and other advances with respect to government regulation and more general acceptance of cryptocurrency by commercial businesses, the Company believes these circumstances bolster the strength of its internal forecasts and enhance the viability of its new business development strategy. The Company believes that it has a competitive advantage based on the following factors:

1. Over forty-eight (48) years of developing and manufacturing advanced power solutions to some of the most iconic businesses on the Fortune 500.
2. The ability to leverage its existing infrastructure, capacity and excess space at the various manufacturing facilities of Digital Power and its subsidiaries. These facilities comply with applicable governmental or military requirements with agency-issued certificates corroborating these facts. Moreover, each facility has readily available military-grade power solutions to operate digital mining operations. The Company believes its ability to exploit the inherent attributes of its facilities in Northern and Southern California, Connecticut and Great Britain will reduce initial costs and help shorten the time requirement to establish digital mining operations at these locations.
3. The thirteen (13) years of technical and practical experience of IMG in Information Technology such as server administration, network engineering or, in this case, digital mining farms.

IMG Network’s expertise lies in information technology, software development, network engineering, and web development and programming. IMG serves both commercial and defense contracts. IMG is involved with several governmental contract vehicles including the U.S. Navy’s Seaport-E and the GSA Stars II Governmentwide Acquisition Contract. IMG Networks, a division of Imagine Media Group, LLC, is a California limited liability company formed in 2004. IMG holds several small business certifications at all government levels including a Small Business Administration (SBA) 8(a), a Small Business designation with the California Department of General Services, and ELBE with the City of San Diego. As a service provider, the core competency of IMG is contract management; in addition, in its capacity as a solutions provider, IMG combines a wide array of technical expertise with a customer-centric philosophy focused on meeting mission needs.

The Company also disclosed today that it has been made aware of numerous unfounded and unsubstantiated inquiries and rumors but cannot address each and every one of them. However, Digital Power reminds all shareholders, investors and the public that its many years of manufacturing quality products, cultivation and retention of long-term clients and leading innovation should speak for itself as the Company continues to pursue new endeavors while expanding current revenue streams for the benefit of all interested parties. To maintain the maximum transparency with shareholders, investors and the public, the Company intends to use its best efforts to provide complete and contemporaneous disclosure of its operations.

The Company also reminds shareholders, investors and the public that it will be hosting an online webinar for its shareholders, investors and the public on Wednesday, December 20, 2017, upon the close of the financial markets that day. All individuals interested in participating in the webinar can email the Company to participate at info@digitalpowercorp.com.

ABOUT DIGITAL POWER

Headquartered in Fremont, CA, Digital Power Corporation, through its subsidiaries, designs, manufactures and sells high-grade customized and off-the-shelf power system solutions. Our products are used in the most demanding communications, industrial, medical and military applications where customers demand high density, high efficiency and rugged power solutions. The Company’s wholly owned subsidiary, Coolisys Technologies, Inc., is dedicated to providing world-class technology-based solutions where innovation is the main driver for mission-critical applications and lifesaving services. Coolisys’ growth strategy targets core markets that are characterized by “high barriers to entry” and include specialized products and services not likely to be commoditized. Coolisys Technologies, Inc., a developer and manufacturer that services the defense, aerospace, medical and industrial sectors, has three subsidiaries including Digital Power Limited dba Gresham Power Ltd., www.GreshamPower.com, a manufacturer based in Salisbury, UK.; Microphase Corporation, www.MicroPhase.com with its headquarters in Shelton, CT 1- 203-866-8000; and Power-Plus Technical Distributors, www.Power-Plus.com, a wholesale distributor based in Sonora, CA 1-800-963-0066.

Digital Power Lending, LLC, is a wholly owned subsidiary of the Company, is based in Fremont, CA, and is a California private lending company dedicated to strategically providing capital to small and middle size businesses for an equity interest in addition to loan fees and interest, www.DigitalPowerLending.com. Excelo, LLC, a wholly-owned subsidiary of the Company, is a national search firm specializing in fulfilling strategic executive, professional and hi-tech placements for businesses delivering world-class services, www.Excelo.com. Digital Power Corporation’s headquarters is located at 48430 Lakeview Blvd., Fremont, California, 94538; 1-877-634-0982; www.DigiPwr.com.

For Investor inquiries: IR@digipwr.com, www.DigitalPowerCorp.com or 1-888-753-2235.

Forward-Looking Statements

The foregoing release contains “forward looking statements” regarding future events or results within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements concerning the Company’s current expectations regarding revenues for the remaining 2017 and thereafter from contracts and operations on a consolidated basis, the Company’s ability to continue to finance its current operations, the ability of the Company to finance or complete the manufacturing of its new product line for the digital mining community, the ability of the Company to sell digital mining power systems or the ability to raise sufficient capital to establish digital mining farms or its ability to operate successfully those farms and be profitable. The Company cautions readers that such “forward looking statements” are, in fact, predictions that are subject to risks and uncertainties and that actual events or results may differ materially from those anticipated events or results expressed or implied by such forward- looking statements. The Company disclaims any current intention to update its “forward looking statements,” and the estimates and assumptions within them, at any time or for any reason, unless required by applicable law. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company’s website at www.DigitalPowerCorp.com.

$CIIX Plan to Spin Off CBD Biotechnology & ChineseHempOil.com

CBD Biotechnology Co. Ltd. Announces Acquisition of Chinese Wholesale Alcohol License

SAN GABRIEL, California, December 13, 2017 —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (‘CIIX’ or the ‘Company’), the premier financial information website for Chinese-speaking investors, today announces plans to spin off its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., and its wholly-owned subsidiary, ChineseHempOil.com, Inc., to be registered as a separate publically traded company allowing CIIX to focus on its new Cryptocurrency Division and its Core Financial Education Business. The Company’s Board of Directors approved plans to spin off the Consumer Products Division in both the United States and China, which includes its hemp oil assets and its new wholesale alcohol distribution business, at the end of February 2018. The Company will take appropriate steps for the shares of the subsidiary’s common stock to be listed for trading on the OTC:QB. The Company hopes to emulate the success it experienced in incubating Medicine Man Technologies, Inc. (“MDCL”) as it transitioned from a private startup company to successful public company.

“We are excited to announce our intention to spin off CBD Biotechnology and ChineseHempOil.com, Inc. as we believe the existing business lines and the new acquisitions in China, secured by CEO Summer Yun, will allow these entities to continue to grow in their respective markets, while bringing new value to the Company’s existing shareholders. The details about the value to the Company’s existing shareholders will be announced in the coming weeks,” says ChineseInvestor.com, Inc.’s CEO Warren Wang.

CBD Biotechnology Co. Ltd. has recently acquired a Wholesale Alcohol License in China thereby expanding its Chinese consumer division to include distribution of “baijiu,” the grain liquor known as the toast of choice for the Chinese. On November 7, 2017, CBD Biotechnology was issued Wholesale Alcohol License from the ShangHai Wine Monopoly Bureau effective October 24, 2107 for a three year term.

CBD Biotechnology has also entered into a wholesale agreement with China GuiZhou HanTai Wine, Inc. to distribute its brand of baijiu, Yantai 1985, and has kicked off its sales and marketing plan by partnering with Jinri Toutiao (translation: Today’s Headlines), a popular Chinese mobile application just in time to launch for the Chinese New Year.  Founded in 1979, China GuiZhou HanTai Wine, Inc.’s top-selling baijiu brand, Yantai 1985, is produced in the town of Maotai in China’s Guizhou province. Moutai is renowned for having the purest water in China; therefore, spirits produced in Moutai have a distinct taste and pleasing aroma attributable to the use of local water in the production.

Today’s Headlines, the first broad news aggregator app in China, with content ranging from real-time news to music, movies, games, and shopping, is one of the most popular and fastest growing mobile apps in China with over 600 million registered users.  Today’s Headlines provides CBD Biotechnology a cost effective, convenient, and trustworthy platform to directly connect with millions of users to market Yantai 1985, the CBD Magic Hemp Series skincare line and other complimentary consumer product lines it may identify in the near future. Reports indicate that online sales of alcohol beverages in China will double by 2020 as more consumers look for product information online before buying. Through its relationship with China GuiZhou HanTai Wine, Inc. and Today’s Headlines, CBD Biotechnology hopes to capitalize on this growing consumer trend to expand its brand awareness and achieve sustainable revenue growth.

According to Summer Yun, CEO of CBD Biotechnology Co. Ltd., “The decision to expand CBD Biotechnology’s Chinese Consumer Division to include baijiu liquor sales is part of a strategic plan to increase revenues in the coming year. By aligning with China GuiZhou HanTai Wine, Inc., CBD Biotechnology has partnered with a proven leader in the Chinese baijiu market. In addition to distribution rights, the agreement between CBD Biotechnology and China GuiZhou HanTai Wine, Inc. affords CBD Biotechnology the opportunity to launch its own brand of baijiu in the future.” Ultra-premium baijiu volumes are expected to jump by 16% a year over the next five years as the number of high earners in China soars, a new report has said, providing CBD Biotechnology a huge opportunity to gain significant market share in this growing industry.

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom;

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

$BSQR Partners with $AMZN $MSFT Industrial IoT Data Visualizations

Amazon QuickSight and Microsoft’s Power BI help DataV customers rapidly build and share custom cross-system reports that include complex and critical IIoT data

BELLEVUE, Wash., Dec. 12, 2017  — Bsquare (NASDAQ: BSQR), a provider of Industrial Internet of Things (IIoT) solutions, today announced new DataV software integrations with Amazon QuickSight and Microsoft’s Power BI that allow industrial organizations to quickly create and share powerful new cross-system interactive data visualizations and reports. Customers can now leverage these popular reporting platforms to take connected device information from within DataV and combine it with other enterprise system data to create new data views that can be critical for business success.

“Data generated from connected equipment is allowing industrial companies to make quicker and more accurate decisions about their business,” said Dave McCarthy, Senior Director, Products at Bsquare. “The ability to quickly create new visualizations of that information by combining it with other data – and easily sharing the results with others in the organization – is critical to achieving that goal. DataV currently offers native reporting based on the functionality within our apps. By providing an open standard connection to tools from third party vendors like Amazon and Microsoft, we’re helping customers extend the value they can get out of their IIoT data sets.”

With connected endpoints in businesses poised to grow from 3 billion in 2017 to 7.5 billion by 2020, being able to capture device data and turn it into actionable intelligence is fundamentally changing how industrial organizations operate. From predicting equipment failures to better utilization of assets, DataV already helps organizations drive powerful business outcomes from connected device data. These new integrations help extend the functionality of DataV so customers can build even more powerful cross-system visualizations and reports. Teams can create custom visualizations or select from a list of pre-built reports that map to the apps available in DataV.

DataV enables industrial organizations, such as those in manufacturing, transportation, and oil and gas industries to use data generated by connected devices to make smarter operational decisions. DataV IoT applications and platform help businesses translate insights generated by industrial assets into critical operational improvements, such as better managing devices, increasing production volume, or reducing operating costs. Visualization tools are a critical component to realizing these and other benefits from IIoT.

Amazon QuickSight is a fast, cloud-powered business analytics service that makes it easy to build visualizations, perform ad-hoc analysis, and quickly get business insights from data. Power BI from Microsoft is a suite of business analytics tools that enable organizations to connect to hundreds of data sources, simplify data prep and drive analysis. Rich, custom visualizations can be viewed from browsers or mobile devices. DataV also integrates with the Tableau visual analytics platform.

To learn more about how DataV is driving powerful business outcomes from IIoT, visit: https://www.bsquare.com/datav/

About Bsquare
For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes. Bsquare DataV software solutions can be deployed by a wide variety of enterprises to create business-focused Internet of Things (IoT) systems that more effectively monitor device data, automate processes, predict events and produce better business outcomes. Bsquare goes a step further by coupling its purpose-built DataV software with comprehensive analytic and engineering services that can help organizations of all types make IoT a business reality. For more information, visit www.bsquare.com.

BSQUARE, the BSQUARE Logo and DataV are trademarks of BSQUARE Corporation in the U.S. and other countries. Other names and brands herein may be trademarks of others.

$GLYC Improvements in Median Overall Survival Phase 1/2 Trial for GMI-1271 in AML

ROCKVILLE, Md.

GlycoMimetics, Inc. (NASDAQ: GLYC) today announced updated data from the Phase 1/2 trial evaluating the safety, tolerability and efficacy of GMI-1271 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and in older adults with newly diagnosed AML, including the following conclusions:

For patients with R/R AML treated at the Phase 2 dose (n = 54) and for whom median follow up was 6.6 months:

• Clinical remission (CR+CRi) was 43%.
• Median overall survival was 9.4 months (95% CI: 5.7 – 15.1 months; calculated by Kaplan Meier method). This compares favorably to a median overall survival of up to 5.4 months reported for historical, matched controls treated with mitoxantrone, etoposide and cytarabine (MEC) alone. ^1,2
• Median duration of remission was 11.1 months (95% CI: 5.8-NA; calculated by Kaplan Meier method).

For older patients with newly diagnosed disease (n=25) and for whom median follow up was 10.5 months:

• Clinical remission rate was 68%.
• Median overall survival was 15.8 months (95% CI: 10.3 – NA; calculated by Kaplan Meier method). This compares favorably to a historical median overall survival of approximately 12 months in matched controls treated with 7+3 chemotherapy alone. ^3,4
• Median duration of remission was 14.8 months (95% CI: 8.3 – NA; calculated by Kaplan Meier method).
• Median event free survival was 11.3 months.

The data were presented yesterday during an oral scientific session at the 59th American Society of Hematology (ASH) Annual Meeting and Expo in Atlanta.

Across both populations, GMI-1271 was well tolerated with no obvious incremental toxicity observed and lower than expected rates of severe, debilitating, grade 3-4 mucositis reported (e.g., 3% incidence reported vs. historical 20-25% incidence with MEC alone).

“These new data from our Phase 1/2 clinical trial demonstrate that encouraging clinical outcomes are possible for both duration of remission and survival endpoints when GMI-1271 is added to chemotherapy in two distinct AML patient populations,” noted Helen Thackray, M.D., FAAP, GlycoMimetics Senior Vice-President, Clinical Development and Chief Medical Officer. “Beyond the high response rates previously reported with GMI-1271, we can now point to additional long-term endpoints that further support our plan to move the drug candidate into a Phase 3 clinical trial scheduled to begin in mid-2018. Importantly, with respect to safety, the low mucositis rate in relapsed and refractory patients receiving MEC induction chemotherapy — where you would expect around 25% severe mucositis — is quite striking. This was predicted and explained by preclinical models in which GMI-1271 blocked inflammatory macrophages trafficking to the gut and thus prevented mucosal injury.”

“These results continue to show that AML patients treated with GMI-1271 consistently perform better than expected,” said Daniel J. DeAngelo, M.D., Ph.D., the trial’s lead investigator and Director of Clinical and Translational Research, Adult Leukemia Program, at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, who presented the data at the ASH Annual Meeting. “Our Phase 2 population consists of very high-risk patients based on age, disease status, and cytogenetic risk factors. The updated data continue to support the concept that disrupting the relationship between leukemic cells and the protective bone marrow microenvironment, when combined with chemotherapy, could improve the outlook and prognosis for these patients.”

The second oral presentation at the ASH meeting highlighted a preclinical study in murine models of AML in which E-selectin was shown to be upregulated, and AML cells binding to E-selectin increased chemo-resistance by activating specific tumor cell survival signaling pathways. This effect within the bone marrow microenvironment is unique to E-selectin as compared to other vascular adhesion molecules and can be blocked by GMI-1271. This translational research provides important evidence that elucidates how treatment with GMI-1271 appears to be improving sensitivity to chemotherapy.

“Given response rates we’ve observed to date that suggest clinical benefit in combination with chemotherapy in two AML populations, this preclinical work provides important further support for the mechanism of action of GMI-1271,” noted Dr. Thackray. “Together, the clinical and preclinical data we have shared at the ASH Annual Meeting demonstrate that GMI-1271 could represent a novel and truly differentiated approach to treatment of AML,” Dr. Thackray concluded.

Meeting abstracts are available on ASH’s website.

GlycoMimetics to Hold Post-ASH Meeting Briefing in Boston on December 19

GlycoMimetics will hold a briefing for investors/analysts, which will also be available via webcast, to review the GMI-1271 program with a focus on the AML clinical data presented at the ASH Annual Meeting, at the Langham Hotel in Boston, December 19, at 7:30 a.m. EST. Dr. DeAngelo will present the clinical data from the ASH oral presentation and respond to questions from on-site participants.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ first drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics’ wholly-owned drug candidate, GMI-1271, a specific E-selectin antagonist, has been evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in an ongoing Phase 1 clinical trial for the treatment of multiple myeloma. The U.S. Food and Drug Administration has granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also conducted a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding the clinical development of GMI-1271, including the expected timing of clinical trials and the presentation of clinical data. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the company’s annual report on Form 10-K that was filed with the U.S. Securities and Exchange Commission (SEC) on March 1, 2017, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

References

1. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of clinical oncology. 2005;23(18):4110-4116. 47.

2. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). Journal of clinical oncology. 2004;22(6):1078-1086

3. Foran JM, Sun Z, Claxton DF, et al. North American Leukemia, Intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age≥ 60 years): A trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood. 2015;126(23):217-217. 45.

4. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239-3246.

$TIK $1,000,000 in New Orders, Including over $540,000 in International Mode 5 Orders

EAST RUTHERFORD, N.J.

Tel-Instrument Electronics Corp. (“Tel”, “Tel-Instrument” or the “Company”) (NYSE American: TIK), a leading designer and manufacturer of avionics test and measurement solutions, today announced that last week it received over $1,000,000 in orders from four (4) customers, including $543,000 of international Mode 5 orders and $442,000 in orders from our commercial distributor, primarily for a major U.S. airline.

In commenting on the results, Mr. Jeffrey O’Hara, President and CEO of Tel, stated, “We have seen a solid pick-up in orders from both our domestic and international customers this quarter with sales being made to several of our key international Mode 5 markets. Orders for our new T-47/M5 product continue to increase and we will begin shipping this product to customers later this month. The T-47/M5 is a key product for the Company as it can also be sold as a Mode 5 upgrade KIT for the thousands of Mode 4 test sets already in the field. The Company continues to pursue international opportunities with its “Drive to Mode 5” marketing campaign. Rebuilding our sales backlog is critical, and we expect to see this sales momentum continue in calendar year 2018 as we approach the January 1, 2020 mandate for Mode 5 inter-operability with our foreign allies.

We hope to see all of our shareholders at our Annual Meeting scheduled for January 17, 2018 at our East Rutherford offices.

About Tel-Instrument Electronics Corp.

Tel-Instrument is a leading designer and manufacturer of avionics test and measurement solutions for the global commercial air transport, general aviation, and government/military aerospace and defense markets. Tel-Instrument provides instruments to test, measure, calibrate, and repair a wide range of airborne navigation and communication equipment. For further information please visit our website at www.telinstrument.com.

This press release includes statements that are not historical in nature and may be characterized as “forward-looking statements,” including those related to future financial and operating results, benefits, and synergies of the combined companies, statements concerning the Company’s outlook, pricing trends, and forces within the industry, the completion dates of capital projects, expected sales growth, cost reduction strategies, and their results, long-term goals of the Company and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts. All predictions as to future results contain a measure of uncertainty and, accordingly, actual results could differ materially. Among the factors which could cause a difference are: changes in the general economy; changes in demand for the Company’s products or in the cost and availability of its raw materials; the actions of its competitors; the success of our customers; technological change; changes in employee relations; government regulations; litigation, including its inherent uncertainty; difficulties in plant operations and materials; transportation, environmental matters; and other unforeseen circumstances. A number of these factors are discussed in the Company’s previous filings with the U.S. Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 (the “Act”) protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Tel-Instrument Electronics Corp.
Joseph P. Macaluso, 201-933-1600
or
Institutional Marketing Services (IMS)
John Nesbett or Jennifer Belodeau
203-972-9200
jnesbett@institutionalms.com

$PTI Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 12, 2017 — Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it intends to offer and sell, subject to market and other conditions, 7,000,000 shares of its common stock in an underwritten public offering. As part of this offering, Proteostasis intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent, or 1,050,000 shares, of the common stock offered in the public offering.  All of the shares to be sold in the offering are to be sold by Proteostasis.

Leerink Partners LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as lead manager for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered by Proteostasis pursuant to a shelf registration statement (File No. 333-218545), which was declared effective by the Securities and Exchange Commission (SEC) on July 3, 2017.  The offering will be made only by means of a preliminary prospectus supplement and accompanying prospectus.  When available, copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525, ext. 6132 or by email at syndicate@leerink.com and from RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8^th Floor, New York, NY 10281, Telephone: (877) 822-4089, Email: equityprospectus@rbccm.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. Headquartered in Cambridge, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. In addition to its multiple programs in cystic fibrosis, Proteostasis Therapeutics has formed a collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding Proteostasis’ expectations of the completion and timing and size of the proposed public offering. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Proteostasis’ business, including those described in the company’s periodic filings with the SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Proteostasis can be found under the heading “Risk Factors” in the Company’s periodic reports, including its annual report on Form 10-K for the year ended December 31, 2016, its quarterly report on Form 10-Q for the quarter ended September 30, 2017, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof, each available on the SEC’s web site at www.sec.gov. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

CONTACTS:

Investors:
David Pitts
Argot Partners
212.600.1902
david@argotpartners.com

Media:
Eliza Schleifstein
Argot Partners
973.361.1546
eliza@argotpartners.com

$EMMBF Provides Business Update for 2018

TORONTO, Dec. 04, 2017 — Emblem Corp. (“Emblem” or the “Company”) (TSXV:EMC), a vertically integrated cannabis company focused on research, development, production and distribution of cannabis products for medical purposes, announced today its growth plans for 2018.

Incoming President and CEO, Nick Dean, who brings years of consumer marketing, retail and leadership experience to Emblem’s dedicated team, will be moving forward under a new paradigm focused on building capacity to meet the expected surge in demand, ramping up patient acquisition on the medical cannabis market, and embarking on a number of strategic partnerships that will position it well for the adult-use cannabis market.

“We will be entering a new era when Canada finally removes the stigma and legalizes adult-use cannabis,” noted Dean. “We intend on leveraging our award-winning customer experience, our significant strengths in the medical segment and our dedicated focus on providing the highest quality products to become a major player in the recreational segment as well.”

Emblem currently has over 8,500 square feet of flowering capacity at its closed box facility in Paris, Ontario. The Company’s recent major land acquisition will soon pave the way for state-of-the-art greenhouse facilities that will significantly expand the Company’s total production capacity to upwards of 17,000 kilograms of dried flower per annum.

“With our oils license now in place and the adult-use market on the horizon, we are looking to significantly increase our cultivation capacity, while at the same time maintaining our commitment to produce high-quality product at low cost,” says Dean. “Ultimately it’s about being relentlessly driven to deliver a strong return on investment and a solid balance sheet. We will also be mindful of strategic transactions and other opportunities to accelerate our growth objectives in Canada and international markets.”

Emblem remains focused on the production of the highest quality cannabis flower and derivative products through a multi-pronged approach of “closed box” and “greenhouse” production facilities. The Company views having parallel paths and the optionality of both types of cultivation facilities available as a prudent approach to maximizing return on capital employed.

About Emblem

Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on Toronto Venture Exchange (TSXV).

Forward-looking statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (together, “forward-looking statements”). All statements and information contained herein that is not clearly historical in nature may constitute forward-looking statement. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company’s annual information form dated October 18, 2017 which has been filed with the Canadian Securities Administrators and is available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ali Mahdavi
Vice President, Capital Markets and Investor Relations
Emblem Corp.
(416) 962-3300
alimahdavi@emblemcorp.com

$RIOT TessPay Signs Letter of Intent for Merger with Cresval Capital

CASTLE ROCK, Colo., Dec. 11, 2017 – Riot Blockchain Inc. (Nasdaq: RIOT) (the “Company”) today announced that its majority owned Tess Inc. (“TessPay”) has entered into a non-binding letter of intent (“LOI”) to merge with Cresval Capital Corp. (“Cresval”) (TSX-V: CRV). TessPay is a blockchain company developing a supply chain payment platform for businesses to attempt to guarantee payment on time and in full.  After the closing of the anticipated merger, TessPay will be publically traded on the TSX Venture Exchange (the “TSXV”) and change its name to “TessPay Inc.”.

The LOI provides that TessPay will be issued 80,000,000 shares of Cresval, and the present shareholders of Cresval will retain 8,400,000 shares of the combined company TessPay post-merger. Riot Blockchain will receive 41,600,000 shares resulting from its 52% ownership of TessPay.

Assuming that TessPay and Cresval enter into a definitive agreement, the parties expect that the merger can be completed by the 2^nd quarter of 2018. No assurance can be given that a definitive agreement will be entered into, that the proposed merger will be consummated, or that the combined company will be able to obtain adequate funds needed to fund its business plan.

The merger would be the first of Riot Blockchain’s investments to become a stand-alone public company. Haywood Securities Inc acted as a financial advisor on the transaction.

Jeff Mason, Chief Executive Officer of TessPay, stated, “The decision to take the company public provides us access to traditional capital markets as we continue developing our blockchain technology solution. This environment will also foster transparency and accountability moving forward, providing confidence to investors and prospective customers alike.”

The blockchain is a decentralized and encrypted ledger that offers a secure, efficient, verifiable and permanent way of storing records and other information without the need for intermediaries. These protocols are the backbone of numerous digital currencies, including Bitcoin, Ethereum and Litecoin. Blockchain protocols have a wide range of use, including processing transactions, accounting, verification and proof of ownership across a far-reaching spectrum of applications.

About Riot Blockchain

Riot Blockchain, Inc. is leveraging its expertise and a network of professional advisors to build and support blockchain technologies.  It is establishing an Advisory Board with technical experience intending to become a leading authority and supporter of blockchain, while providing investment exposure to the rapidly growing Bitcoin and blockchain ecosystems. For more information, visit http://www.RiotBlockchain.com/.

About TessPay

TessPay is a blockchain company developing a payments ecosystem for component and sub-component supply chain settlements (payments). TessPay believes a transition will occur from the present state wherein payments down a supply chain are essentially manual (triggered by a manager or trusted party) to a blockchain protocol that mandates simultaneous payment of all component and sub-component suppliers when the primary party makes a payment into the chain.

TessPay intends to develop and utilize TessPay Smart Contracts, wherein a payment from the primary party in the chain would be automatically apportioned to all other eligible parties in the chain concomitant with payment by the primary party. The creditworthy financial condition of the primary party would facilitate lender involvement in the supply chain under the security afforded by the TessPay Smart Contract.  The first TessPay smart contracts payment system will be tailored to the needs of the international telecommunications industry in respect of cross border telephone calls. For more information, visit http://tesspay.io/.

Safe Harbor

The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipates,” “plans,” “expects,” “intends,” “will,” “potential,” “hope” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company’s periodic filings with the Securities and Exchange Commission, including the factors described in the sections entitled “Risk Factors”, copies of which may be obtained from the SEC’s website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Media Contacts
Karen Chase or Travis Kruse
Russo Partners, LLC
(646) 942-5627
(212) 845-4272
karen.chase@russopartnersllc.com
travis.kruse@russopartnersllc.com

Investor Contact
IR@RiotBlockchain.com